A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ACUTE, CHRONIC PAIN AND/OR NEUROPATHIC PAIN AND MIGRAINES

Abstract: Pharmaceutical compositions are disclosed for the treatment of acute, chronic and/or neuropathic pain. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an analgesic agent and a pharmaceutically acceptable carrier. The analgesic agent is selected from opioid analgesics, NMDA antagonists, substance P antagonists, COX 1 and COX 2 inhibitors, tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), capsaicin receptor agonists, anesthetic agents, benzodiazepines, skeletal muscle relaxants, migraine therapeutic agents, anti-convulsants, anti-hypertensives, anti-arrythmics, antihistamines, steroids, caffeine, and botulinum toxin. The method of using these compounds and a method of treating acute, chronic and/or neuropathic pain and migraine in a mammal including a human is also disclosed.

Description: A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ACUTE, CHRONIC PAIN AND/OR NEUROPATHIC PAIN AND MIGRAINES Background of the Invention The present invention relates to pharmaceutical compositions for the treatment of acute, chronic and/or neuropathic pain and migraine in a mammal (e g human) comprising a nicotine receptor partial agonist (NRPA) and analgesic agents, including opioid analgesics, NMDA antagonists, substance P antagonists, COX 1 and COX 2 inhibitors , tπcyclic antidepressants (TCA) selective serotonin reuptake inhibitors (SSRI), capsaicin receptor agonists, anesthetic agents, benzodiazepines, skeletal muscle relaxants, migraine therapeutic agents anti-convulsants, anti-hypertensives, anti-arrythmics, antihistamines, steroids, caffeine, N-type calcium channel antagonists and botulinum toxin The term NRPA refers to all chemical compounds which bind at neuronal nicotinic acetylchohne specific receptor sites in mammalian tissue and elicit a partial agonist response A partial agonist response is defined here to mean a partial, or incomplete functional effect in a given functional assay Additionally, a partial agonist will also exhibit some degree of antagonist activity by its ability to block the action of a full agonist (Feldman, R S , Meyer, J S & Quenzer, L F Principles of Neuropsychopharmacology, 1997, Sinauer Assoc Inc ) The present invention may be used to treat mammals (e g humans) for acute, chronic and/or neuropathic pain with a decrease in the seventy of unwanted side effects such as causing nausea and/or stomach upset. The invention also relates to aryl fused azapolycyhc compounds that bind to neuronal nicotinic acetylchohne specific receptor sites and are useful in modulating cholinergic function and are referred to in WO 9818798-A1 , WO 9935131 -A1 and WO 9955680-A1 The foregoing applications are owned in common with the present application and are incorporated herein by reference in their entireties Analgesic agents decrease pain perception In animal models of pain states, the above compounds inhibit acute pain perception These compounds also inhibit pain sensitization processes in which the perception of the painfulness of a given stimulus is increased without any change in stimulus intensity In humans, analgesic agents have also been found to decrease both acute pain perception and sensitization Opioid analgesic agents, in particular, remain the most effective means of alleviating severe pain across a broad spectrum, including inflammatory as well as neuropathic pain states However, even though analgesic agents have therapeutic utility in the treatment of pain, there are significant liabilities to the use of analgesic compounds Specifically, many of these compounds that have been tested in humans can cause potentially serious side effects such as gastrointestinal complications including nausea, emesis, ulcers, and constipation, respiratory depression, and psychological and physical dependence Summary of Invention The present invention relates to a pharmaceutical composition for the treatment of acute, chronic and/or neuropathic pain and migraine comprising (a) a nicotine receptor partial agonist or a pharmaceutically acceptable salt thereof, (b) an analgesic agent or pharmaceutically acceptable salt thereof and (c) a pharmaceutically acceptable carrier, wherein the active agents "a" and "b" above are present in amounts that render the composition effective in treating acute, chronic and/or neuropathic pain, and migraine A nicotinic partial agonist combined with an analgesic agent may inhibit pain sensitization and pain perception while reducing the incidence of undesirable side effects A nicotinic partial agonist combined with an analgesic agent may inhibit pain sensitization and pain perception while reducing the incidence of undesirable side effects Nicotine has long been appreciated to have antinociceptive properties, but its use has been limited by a poor spectrum of activity, side effects, and less efficacy than opioids This may be due to a lack of specificity of nicotine for neuromuscular, ganglionic, and central nervous system receptors The development of nicotine partial agonists with specific receptor subtype affinities is an approach to potentially reduce side effects and enhance efficacy In a more specific embodiment of the invention the analgesic agent is selected from opioid analgesics, NMDA antagonists, substance P antagonists, COX 1 and COX 2 inhibitors, tncyclic antidepressants (TCA) selective serotonin reuptake inhibitors, (SSRI), capsaicin receptor agonists, anesthetic agents, benzodiazepines, skeletal muscle relaxants, migraine therapeutic agents, anti-convulsaπts, anti-hypertensives, anti-arrythmics, antihistamines, steroids, caffeine, N-type calcium channel antagonists and botulmum toxin In another more specific embodiment of this invention, the nicotine receptor partial agonist is selected from 9-bromo-1 ,2,3,4,5.6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-chloro-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1.2-a][1 ,5]dιazocιn-8-one, 9-fluoro-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-ethyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-methyl-1 ,2,3,4,5.6-hexahydro-1 ,5-methano-oyndo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-phenyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-vιnyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-bromo-3-methyl-1 ,2,3,4 5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2-a][1 ,5]dιazocιn-8- one 3-benzyl-9-bromo-1 ,2,3,4.5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2-a][1 ,5]dιazocιn-8- one, 3-benzyl-9-chloro-1 ,2,3 4,5 6-hexahydro-1 ,5-methano-pyrιdo[1 ,2-a][1 ,5]dιazocιπ-8- one, 9-acetyl-1 ,2,3 4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-ιodo-1 ,2,3,4,5,6-hexahydro-1 5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-cyano-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-ethynyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιπ-8-one, 9-(2-propenyl)-1 ,2,3,4,5 6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-(2-propyl)- 1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-carbomethoxy-1 ,2,3 4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-carboxyaldehyde-1 2 3 4 5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-(2,6-dιfluorophenyl)-1 .2,3,4 5 6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-phenyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-(2-fluorophenyl)-1 ,2,3 4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-(4-fluorophenyl)-1 ,2,3 4,5 6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-(3-fluorophenyl)-1 ,2,3 4,5 6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-(3,5-dιfluorophenyl)-1 ,2,3,4,5 6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-(2,4-dιfluorophenyl)-1 .2 3 4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-(2,5-dιfluorophenyl)-1 2,3,4,5 6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8- one, 6-methyl-5-oxo-6, 13-dιazatetracyclo[9 3 1 0 2 10 0 4 8 ]pentadeca-2(10),3,8-tπene, 5-0X0-6,13-dιazatetracyclo[9 3 1 0 2 10 0 4 B ]pentadeca-2(10),3,8-tπene, 6-oxo-5,7, 13-tπazatetracyclo[9 3 1 0 2 10 0 4 8 ]pentadeca-2(10),3,8-tπene, 4,5-dιfluoro-10-aza-trιcyclo[6 3 1 0 2 7 ]dodeca-2(7),3,5-tπene, 5-fluoro-10-aza-trιcyclo[6 3 1 0 2 ']dodeca-2(7),3,5-trιene-4-carbonιtπle, 4-ethynyl-5-fluoro-10-aza-trιcyclo[6 3 1 0 2 7 ]dodeca-2(7),3,5-tπene, 5-ethynyl-10-aza-tπcyclo[6 3 1 0 2 ]dodeca-2(7),3,5-trιene-4-carbonιtrιle, 6-methyl-5-thιa-5-dιoxa-6 13-dιazatetracycio[9 3 1 0 2 10 0 4 8 ]pentadeca-2(10),3,8- tπene, 10-aza-tπcyclo[6 3 1 0 " ]dodeca-2(7),3,5-tπene, 4-fluoro-10-aza-trιcyclo[6310 27 ]dodeca-2(7),3,5-trιene, 4-methyl-10-aza-tπcyclo[6310 2" ]dodeca-2(7),3,5-trιene, 4-tπfiuoromethyl-10-aza-tπcyclo[6310 27 ]dodeca-2(7),3,5-trιene, 4-nιtro-10-azatrιcyclo[631 θ " ]dodeca-2(7),3,5-trιene, 7-methyl-5,7,13-tπazatetracyclo[9310 210 0 48 ]pentadeca-2(10),3,5.8-tetraene, 6-methyl-5,7,13-trιazatetracyclo[9310 210 0 48 ]pentadeca-2(10),3,5,8-tetraene, 67-dιmethyl-5,7,13-tπazatetracyclo[9310 210 0 8 ]pentadeca-2(10),3,5,8-tetraeι 6-methyl-7-phenyl-5,7,13-tπazatetracyclo[9310 210 0 48 ]pentadeca-2(10), 3,5,8- tetraene 67-dιmethyl-5814-trιazatetracyclo[10310 211 0 49 ]hexadeca-2(11),3,5,7,9-pentaene, 5814-tπazatetracyclo[10310 211 0 49 ]hexadeca-2(11),3,5,7,9-pentaene, 14-methyl-5,814-trιazatetracyclo[1031 O 211 0 49 ]hexadeca-2(11), 3,5,7, 9-pentaene, 5-oxa-713-dιazatetracyclo[9310 210 0 48 ]pentadeca-2(10).3,6,8-tetraene, 6-methyi-5-oxa-713-dιazatetracyclo[9310 210 0 8 ]pentadeca-2(10),36,8-tetraene, 4-chloro-10-azatπcyclo[6310 2~ ]dodeca-2(7),3,5-tπene, 10-azatrιcyclo[6310 27 ]dodeca-2(7),3,5-tπen-4-yl cyanide, 1-(10-azatπcyclo[6310 2_ ]dodeca-2(7),3,5-trιen-4-yl)-1-ethanone, 10-azatrιcyclo[6310 2 ~]dodeca-2(7) 3,5-trιen-4-ol, 7-methyl-5-oxa-6,13-dιazatetracyclo[9310 210 0 48 ]peπtadeca-2,4(8),6,9-tetraene, 4,5-dιchloro-10-azatrιcyclo[6310 2^ ]dodeca-2(7),3,5-trιene, 11-azatrιcyclo[7310 27 ]trιdeca-2(7),35-trιene-5-carbonιtπle, 1-[11-azatπcyclo[7310 2^ ]trιdeca-2(7),3,5-trιen-5-yl]-1-ethanone, 1-[11-azatπcyclo[7310 2 ]tπdeca-2(7),3,5-trιen-5-yl]-1-propanone, 4-fluoro-11-azatπcyclo[7310~ 7 ]trιdeca-2(7),35-tπene-5-carbonιtrιle 5-fluoro-11-azatπcyclo[7310" ]trιdeca-2(7) 3,5-tπene-4-carbonιtrιle, 6-methyl-7-thιa-5,14-dιazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3,5,8-tetraene, 6-methyl-5,7,14-tπazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3,5,8-tetraene, 6J-dιmethyl-5,7,14-trιazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3,5,8-tetraene, 5,7,14-tπazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3,5,8-tetraene, 5,6-dιmethyl-5,714-tπazatetracyclo[10310 210 0 8 ]hexadeca-2(10),3,6,8-tetraene, 5-methyl-5,714-trιazatetracyclo[10310 21G 0 48 ]hexadeca-2(10), 3, 6,8-tetraene, 6-(trιfluoromethyl)-7-thιa-514-dιazatetracyclo[10310 210 0 48 ]hexadeca-2(10), 3,5,8- tetraene, 5,815-trιazatetracyclo[11310 1 0 49 ]neptadeca-2(11 ),3,5,7,9-peπtaene, 7-methyl-58,15-trιazatetracyclo[1131 O 211 0 49 ]heptadeca-2(11),3, 5, 7, 9-pentaene, 6-methyl-5,815-tπazatetracyclo[11310 211 0 4S ]heptadeca-2(11 ),3, 5, 7, 9-pentaene, 6,7-dιmethyl-5,8,15-trιazatetracyclo[1 1 3 1 0 2 11 0 4 9 ]heptadeca-2(1 1 ), 3, 5,7, 9- pentaene 7-oxa-5, 14-dιazatetracyclo[10 3 1 0 2 10 0 4 8 ]hexadeca-2(10),3,5,8-tetraene, 6-methyl-7-oxa-5 14-dιazatetracyclo[10 3 1 0 2 10 0 4 8 ]hexadeca-2(10),3,5,8-tetraene, 5-methyl-7-oxa-6 14-dιazatetracyclo[10 3 1 0 2 10 0 8 ]hexadeca-2(10),3,5,8-tetraene, 6-methyl-5-oxa-7 14-dιazatetracyclo[10 3 1 0 2 10 0 4 8 ]hexadeca-2(10).3, 6,8-tetraene, 7-methyl-5-oxa-6 14-dιazatetracyclo[10 3 1 O 2 10 0 8 ]hexadeca-2(10),3,6,8-tetraene, 4 5-dιfluoro-1 1 -azatrιcyclo[7 3 1 0 2 7 ]trιdeca-2(7),3,5-tπene, 4-chloro-5-fluoro-1 1 -azatrιcyclo[7 3 1 0 2 7 ]trιdeca-2(7),3,5-trιene, 5-chloro-4-fluoro-1 1 -azatπcyclo[7 3 1 O 2 7 ]trιdeca-2(7),3,5-trιene, 4-( 1 -ethynyl)-5-fluoro-1 1 -azatrιcyclo[7 3 1 0 2 7 ]trιdeca-2(7),3,5-trιene, 5-( 1 -ethynyl)-4-fluoro-1 1 -azatπcyclo[7 3 1 0 2 7 ]tπdeca-2(7),3,5-trιene, 5 6-dιfluoro-1 1 -aza-trιcyclo[7 3 1 0 2 7 ]trιdeca-2,4,6-trιene, 6-trιfluoromethyl-1 1 -aza-tπcyclo[7 3 1 0 2 ']tπdeca-2,4,6-trιene 6-methoxy-1 1 -aza-trιcyclo[7 3 1 0 2 7 ]trιdeca-2(7),3,5-tπene, 1 1 -aza-tπcyclo[7 3 1 0 2 7 ]tπdeca-2(7),3,5-trιen-6-ol, 6-fluoro-1 1 -aza-trιcyclo[7 3 1 0 2 7 ]tπdeca-2(7),3,5-tπene, 1 1 -aza-tncyclo[7 3 1 0 2 7 ]trιdeca-2(7),3,5-tπen-5-ol, 4-nιtro-1 1 -aza-tπcyclot7 3 1 0 2 7 ]trιdeca-2(7),3,5-trιene, 5-nιtro-1 1 -aza-tπcyclo[7 3 1 0 2 7 ]tπdeca-2(7),3,5-tπene, 5-fluoro-1 1 -aza-tncyclo[7 3 1 0 2 ]tπdeca-2(7),3,5-trιene, and 6-hydroxy-5-methoxy-1 1 -aza-tπcyclo[7 3 1 0 2 7 ]tπdeca-2(7),3,5-tπene and their pharmaceutically acceptable salts and their optical isomers Preferably, the nicotine receptor partial agonist is selected from 9-bromo-1 ,2,3,4,5 6-hexahydro-1 ,5-methano-pyrιdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-chloro-1 ,2,3 4,5 6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-fluoro-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-acetyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-ιodo-1 ,2,3,4,5,6-hexahydro-1 5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-cyano-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-carbomethoxy-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-carboxyaldehyde-1 ,2 3,4,5 6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-(2,6-dιfluorophenyl)-1 ,2,3,4,5 6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn- one, 9-phenyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 5]dιazocιn-8-oπe, 9-(2-fluorophenyl)-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8- one, 6-methyl-5-thιa-5-dιoxa-6,13-dιazatetracyclo[9310 210 0 48 ]pentadeca-2(10),3,8- tπene 4-fluoro-10-aza-tπcyclo[6310- ]dodeca-2(7),3,5-trιene, 4-trιfluoromethyl-10-aza-trιcyclo[6310 27 ]dodeca-2(7),3,5-trιene, 4-nιtro-10-azatπcyclo[6310 27 ]dodeca-2(7),3,5-trιene, 6-methyl-5,7,13-trιazatetracyclo[9310 2 ,0 0 48 ]pentadeca-2(10),3,5,8-tetraene, 67-dιmethyl-5,8,14-trιazatetracyclo[10310 211 0 49 ]hexadeca-2(11),3,5,7,9-pentaeπe, 5814-trιazatetracyclo[10310 211 0 49 ]hexadeca-2(11), 3, 5, 7, 9-pentaene, 5-oxa-713-dιazatetracyclo[9310 210 0 48 ]pentadeca-2(10), 3, 6,8-tetraene, 6-methyl-5-oxa-713-dιazatetracyclo[9310 210 0 48 ]pentadeca-2(10),3,6,8-tetraene, 10-azatrιcyclo[6310 27 ]dodeca-2(7), 3, 5-tπen-4-yl cyanide, 1-(10-azatπcyclo[6310 27 ]doαeca-2(7),3,5-tπen-4-yl)-1-ethanone. 11-azatrιcyclo[731 O 2 ]tπdeca-2(7),3,5-trιene-5-carbonιtrιle, 1-[11-azatrιcyclo[7310 27 ]tπdeca-2(7),3,5-trιen-5-yl]-1-ethanone, 1-[11-azatrιcyclo[7310 2 ]trιdeca-2(7),3,5-tπen-5-yl]-1-propaπone, 4-fluoro-11-azatrιcyclo[7310 ^ ]tπdeca-2(7),3,5-tπene-5-carbonιtrιle, 5-fluoro-11-azatrιcyclo[7310 2 ]trιdeca-2(7),3,5-trιene-4-carbonιtπle, 6-methyl-7-thιa-514-dιazatetracyclo[10310 210 0 8 ]hexadeca-2(10),3,5,8-tetraene, 6-methyl-5,7,14-trιazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3,5.8-tetraene, 67-dιmethyl-5,7,14-trιazatetracyclo[10310 210 0 8 ]hexadeca-2(10),3,5,8-tetraene, 6-methyl-7-oxa-5,14-dιazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3,5,8-tetraene, 6-methyl-5-oxa-714-dιazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3, 6,8-tetraene, 5,6-dιfluoro-11-aza-trιcyclo[7310 27 ]tπdeca-246-tπene, 6-tπfluoromethyl-11-aza-trιcyclo[7310 27 ]trιdeca-2,4,6-trιene, 6-methoxy-11-aza-tπcyclo[7310 27 ]trιdeca-2(7),3,5-tπene, 6-fluoro-11-aza-tπcyclo[7310 27 ]trιdeca-2(7),3,5-tπene, and 11-aza-tπcyclo[7310 2' ]tπdeca-2(7),3,5-trιen-5-ol, and their pharmaceutically acceptable salts and their optical isomers In a more specific embodiment of the invention, the analgesic is selected from an opioid analgesic such as propoxyphene (Darvon) meperidine (Demerol), hydromorphone (Dilaudid), hydrocodone (Lortab) morphine, codeine and tramodol, an NMDA antagonist such as dextromethorphan, 2-pιpeπdιπol-1 -alkanol derivatives as described in the United States Patent No 5,272,160 and incorporated herein by reference, eliprodil, and ifenprodil, a COX 2 inhibitor such as rofecoxib or celecoxio a COX 1 inhibitor such as salycylic acid (aspirin), diclofenac, oxicams, indomethacm, ibuprofen, and naproxen, an anticonvulsant, such as gabapentin (Neurontin), carbamazepine, pregabalm, topiramate and valproic acid, a migraine agent such as elitπptan, sumatπptan, πzatπptan, zolmitπptan, and naratπptan, a skeletal muscle relaxant, such as flexeπl, cansoprodol (Soma), robaxisal, norgesic and dantπum, benzodiazepines such as diazepam (Valium), chlordiazepoxide (Librium), alprazolam (Xanax) and lorazepam (Ativan), acetominophen, anesthetic agents such as nitrous oxide, halothane, lidocame etidocaine, ropivacaine, chloroprocaine, sarapin and bupivacaine, capsaicm receptor agonists such as AπthπcareΕ , and TCAs (tπcyclic antidepressants) such as, desipramine amitπptyline, doxepin, perphenazine, protπpty ne and tranylcypromme In another specific embodiment of this invention the analgesic agent is selected from anti- hypertensives such as clonidine, anti-arrythmics such as mexi tene, antihistamines such as diphenhydraimine and hydroxyzine, caffeine, and steroids such as prednisone, methyl- prednisone and decadron, serotonin uptake blockers such as paroxitine, sertraline and fluoxetine. and levodopa In another specific embodiment of the invention the analgesic agents is selected from substance P antagonists and N-type calcium channel antagonists such as ZiconotideCE The invention also relates to a method of treating acute, chronic and/or neuropathic pain and migraine in a mammal comprising administering to said mammal, respectively a pain attenuating effective amount of a pharmaceutical composition comprising (a) a nicotine receptor partial agonist or a pharmaceutically acceptable salt thereof, (b) an analgesic agent or pharmaceutically acceptable salt thereof and (c) a pharmaceutically acceptable carries, wherein the active agents "a" and "b" above are present in amounts that render the composition effective in treating acute, chronic and/or neuropathic pain and migraine In another more specific embodiment of this invention the nicotine receptor partial agonist is selected from 9-bromo-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-chloro-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2-a][1 ,5]dιazocιn-8-oπe, 9-fluoro-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-ethyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-methyl-1 ,2,3,4,5 6-hexahydro-1 ,5-methano-pyrιdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-pheπyl-1 ,2,3,4,5,6-hexahydro-1 5-methano-pyndo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-vιnyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-bromo-3-methyl-1 ,2 3 4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2-a][1 ,5]dιazocιn-8- one, 3-benzyl-9-bromo-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a]f1 ,5]dιazocιn-8- one, 3-benzyl-9-chloro-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8- one, 9-acetyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-ιodo-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyr ιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-cyano-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-ethynyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one; 9-(2-propenyl)-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-(2-propyl)- 1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-carbomethoxy-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-carooxyaldehyde-1 ,2.3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8- one. 9-(2,6-dιfluorophenyl)-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-phenyl-1.2,3 4.5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-oπe, 9-(2-fluorophenyl)-1 ,2,3,4 5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-(4-fluorophenyl)-1 ,2,3,4,5 6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-(3-fluorophenyl)-1 ,2,3,4,5 6-hexahydro-1 ,5-methaπo-pyπdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-(3,5-dιfluorophenyl)-1 ,2,3 4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-(2,4-dιfluorophenyl)-1 ,2,3 4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-(2,5-dιfluorophenyl)-1 ,2 3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8- one, 6-methyl-5-oxo-6,13-dιazatetracyclo[9 3 1 0 2 10 0 4 8 ]pentadeca-2(10),3,8-tπene, 5-0x0-6, 13-dιazatetracyclo[9 3 1 0 2 1 & 0 4 8 ]pentadeca-2(10),3,8-tπene, 6-0X0-5,7, 13-tπazatetracyclo[9 3-1 0 10 0 4 8 ]pentadeca-2(10),3,8-tπene, 4,5-dιfluoro-10-aza-trιcyclo[6 3 1 0 2 ^ ]dodeca-2(7),3,5-tπene, 5-fluoro-10-aza-trιcyclo[6 3 1 0 2 ']dodeca-2(7),3,5-tπene-4-carbonιtπle, 4-ethynyl-5-fluoro-10-aza-tπcyclo[6 3 1 0 2 7 ]dodeca-2(7),3,5-tπene, 5-ethynyl-10-aza-trιcyclo[6 3 1 0 2 ']dodeca-2(7),3,5-tπene-4-carbonιtrιle, 6-methyl-5-thιa-5-dιoxa-6 13-dιazatetracyclo[9 3 1 0 2 10 0 4 8 ]pentadeca-2(10),3,8- tπene, 10-aza-trιcyclo[6 3 1 0 2 " ]dodeca-2(7),3,5-trιene, 4-fluoro-10-aza-tπcyclo[6310 27 ]dodeca-2(7),3,5-trιene, 4-methyl-10-aza-tπcyclo[6310 27 ]dodeca-2(7),3,5-tπene, 4-tπfluoromethyl-10-aza-trιcyclo[6310 2 ']dodeca-2(7),3,5-trιene, 4-nιtro-10-azatrιcyclo[6310 2^ ]dodeca-2(7),3,5-tπene, 7-methyl-57,13-tπazatetracyclo[9310 210 0 48 ]pentadeca-2(10),3,5,8-tetraene, 6-methyl-5,713-trιazatetracyclo[9310 210 0 48 ]pentadeca-2(10),3,5,8-tetraene, 67-dιmethyl-5,7,13-trιazatetracyclo[9310 210 0 48 ]pentadeca-2(10),3,5.8-tetraene, 6-methyl-7-phenyl-5,713-tπazatetracyclo[9310 210 0 48 ]pentadeca-2(10),3,5,8- tetraene 67-dιmethyl-5,814-tπazatetracyclo[10310 211 0 49 ]hexadeca-2(11), 3, 5, 7, 9-pentaene, 5814-tπazatetracyclo[10310 211 0 49 ]hexadeca-2(11),3, 5, 7, 9-pentaene, 14-methyl-58,14-trιazatetracyclo[10310 211 0 49 ]hexadeca-2(11),3,5,7,9-pentaene, 5-oxa-713-dιazatetracyclo[9310 210 0 8 ]pentadeca-2(10), 3, 6,8-tetraene, 6-methyl-5-oxa-7,13-dιazatetracyclo[931 O 2 0 0 48 ]pentadeca-2(10),3.68-tetraene, 4-chloro-10-azatrιcyclo[6310 27 ]dodeca-2(7),3,5-tπene, 10-azatrιcyclo[6310 2 ']dodeca-2(7),3,5-tπen-4-yl cyanide, 1-(10-azatπcyclo[6310 2 ~]dodeca-2(7),3,5-tπen-4-yl)-1-ethanone, 10-azatπcyclo[6310 2^ ]dodeca-2(7),3,5-tπen-4-ol, 7-methyl-5-oxa-6,13-dιazatetracyclo[9310 210 0 48 ]pentadeca-2,4(8),6,9-tetraene, 4,5-dιchloro-10-azatπcyclot6310 27 ]dodeca-2(7),3,5-trιene, 11-azatrιcyclo[7310 2 ']tπdeca-2(7),3,5-tπene-5-carbonιtπle, 1-[11-azatπcyclo[7310 27 ]trιdeca-2(7),3,5-tπen-5-yl]-1-ethanone, 1-[11-azatrιcyclo[7310 ']trιdeca-2(7),3,5-tπen-5-yl]-1-propanone, 4-fluoro-11-azatrιcyclo[731 O 2 ']tπdeca-2(7),3.5-tπene-5-carbonιtπle, 5-fluoro-11-azatπcyclo[731 O 2 ]trιdeca-2(7),3,5-tπene-4-carbonιtrιle, 6-methyl-7-thιa-5,14-dιazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3, 5, 8-tetraene, 6-methyl-5,7,14-tπazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3,5,8-tetraene, 67-dιmethyl-5,7,14-tπazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3,5,8-tetraene, 57,14-trιazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3,5,8-tetraene, 5,6-dιmethyl-5,7,14-trιazatetracyclo[10310 210 0 48 ]hexadeca-2(10), 3, 6, 8-tetraene, 5-methyl-5,714-tπazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3, 6, 8-tetraene, 6-(tπfluoromethyl)-7-thιa-5,14-dιazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3,5,8- tetraene, 5,8,15-tπazatetracyclo[11310 211 0 9 ]heptadeca-2(11), 3, 5, 7, 9-pentaene, 7-methyl-5,8,15-trιazatetracyclo[11310 211 0 49 ]heptadeca-2(11),3,5,7,9-peπtaene, 6-methyl-5,8,15-tπazatetracyclo[11310 211 0 49 ]heptadeca-2(11), 3, 5, 7, 9-pentaene, 6,7-dιmethyl-5,815-tπazatetracyclo[11310 211 0 49 ]heptadeca-2(11 ), 3, 5,7,9- pentaene, 7-oxa-5,14-dιazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3, 5, 8-tetraene, 6-methyl-7-oxa-5,14-dιazatetracyclo[10310 210 0 48 ]hexadeca-2(10) 3.5,8-tetraeπe, 5-methyl-7-oxa-6,14-dιazatetracycio[1031 O 210 0 48 ]hexadeca-2(10),3,5,8-tetraene, 6-methyl-5-oxa-7,14-dιazatetracyclo[10310 210 0 8 ]hexadeca-2(10),3, 6, 8-tetraene 7-methyl-5-oxa-614-dιazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3,6,8-tetraene, 45-dιfluoro-11-azatπcyclo[7310 27 ]trιdeca-2(7),3,5-tπene, 4-chloro-5-fluoro-11-azatπcyclo[7310 2 ']tπdeca-2(7),3,5-tπene, 5-chloro-4-fluoro-11 -azatπcyclo[7310 27 ]tπdeca-2(7),3,5-trιene, 4-(1-ethynyl)-5-fluoro-11-azatπcyclo[7310 27 ]trιdeca-2(7),3,5-tπene 5-(1-ethynyl)-4-fluoro-11-azatrιcyclo[7310 27 ]tπdeca-2(7),3,5-trιene 56-dιfluoro-11-aza-trιcyclo[7310 2 ']tπdeca-2,4,6-trιene, 6-trιfluoromethyl-11-aza-tπcyclo[7310 2 ']tπdeca-246-trιene 6-methoxy-11-aza-tπcyclo[7310 27 ]tπdeca-2(7),3,5-trιene, 11-aza-trιcyclo[7310 2 ']tπdeca-2(7),3,5-tπen-6-ol, 6-fιuoro-11-aza-trιcyclo[7310 27 ]trιdeca-2(7),3,5-trιene, 11-aza-tπcyclo[7310 2" ]tπdeca-2(7),3,5-tπen-5-ol 4-nιtro-11-aza-tπcyclo[7310 27 ]trιdeca-2(7),3,5-trιene, 5-nιtro-11-aza-tπcyclo[7310 27 ]trιdeca-2(7),3,5-trιene, 5-fluoro-11-aza-trιcyclo[7310 2 ']tπdeca-2(7),3,5-tπene, and 6-hydroxy-5-methoxy-11-aza-tπcyclo[7310 27 ]trιdeca-2(7),3,5-tπene and their pharmaceutically acceptable salts and their optical isomers Preferably the nicotine receDtor partial agonist is selected from 9-bromo-1 ,23456-hexahydro-1 ,5-methano-pyrιdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-chloro-1 ,2,34,56-hexahydro-1 ,5-methano-pyrιdo[1.2-a][1 ,5]dιazocιn-8-one, 9-fluoro-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-acetyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-ιodo-1 ,2,34,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-cyano-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-carbomethoxy-12,34,56-hexahydro-15-methano-pyπdo[1,2a][1,5]dιazocιn-8-one, 9-carboxyaldehyde-1,2,3456-hexahydro-1,5-methano-pyrιdo[1,2a][1,5]dιazocιn-8- one 9-(2,6-dιfluorophenyl)-1 ,234,56-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-phenyl-1 ,2,34,56-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-(2-fluorophenyl)-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8- one, 6-methyl-5-thιa-5-dιoxa-6,13-dιazatetracyclo[9310 210 0 8 ]pentadeca-2(10),3,8- tπene, 4-fluoro-10-aza-trιcyclo[6310 27 ]dodeca-2(7),3,5-trιeπe, 4-tπfluoromethyl-10-aza-trιcyclo[6310 27 ]dodeca-2(7),3,5-tπene, 4-πιtro-10-azatπcyclo[6310 27 ]dodeca-2(7),3,5-tπene, 6-methyl-5713-tπazatetracyclo[9310 210 0 48 ]pentadeca-2(10), 3, 5, 8-tetraene, 67-dιmethyl-5,814-trιazatetracyclo[10310 211 0 49 ]hexadeca-2(11),3,5,7,9-peπtaene, 5814-trιazatetracyclo[10310 211 0 4S ]hexadeca-2(11), 3, 5, 7, 9-pentaene, 5-oxa-7,13-dιazatetracyclo[9310 210 0 8 ]pentadeca-2(10), 3, 6, 8-tetraene, 6-methyl-5-oxa-7,13-dιazatetracyclo[9310 210 0 48 ]pentadeca-2(10), 3, 6, 8-tetraene, 10-azatπcyclo[6310 2 ]dodeca-2(7) 3,5-tπen-4-yl cyanide, 1-(10-azatπcyclo[6310 27 ]dodeca-2(7),3,5-tπen-4-yl)-1-ethanone, 11-azatπcyclo[7310 2 ]trιdeca-2(7),35-tπene-5-carbonιtπle, 1-[11-azatπcyclo[7310 27 ]trιdeca-2(7),3,5-trιen-5-yl]-1-ethanone, 1-[11-azatrιcyclo[7310 2 ']trιdeca-2(7),3,5-trιen-5-yl]-1-propanone, 4-fluoro-11-azatrιcyclo|7310 27 ]tπdeca-2(7),3,5-tπene-5-carbonιtrιle, 5-fluoro-11-azatπcyclo[7310' ]tπdeca-2(7),3,5-trιene-4-carbonιtrιle, 6-methyl-7-thιa-514-dιazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3.5,8-tetraene, 6-methyl-5,7,14-tπazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3,5,8-tetraene, 6,7-dιmethyl-5,7,14-trιazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3,5,8-tetraene, 6-methyl-7-oxa-514-dιazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3,5,8-tetraene, 6-methyl-5-oxa-714-dιazatetracyclo[10310 210 0 48 ]hexadeca-2(10), 3,6, 8-tetraene, 56-dιfluor o-11 -aza-tπcyclo[7310 2 ~ ]tπdeca-2,4,6-trιene 6-tπfluoromethyl-11-aza-trιcyclo[7310 27 ]tπdeca-2,4,6-trιene, 6-methoxy-11-aza-trιcyclo[7310 2^ ]trιdeca-2(7),3,5-tπene, 6-fluoro-11-aza-tπcyclo[7310 2" ]tπdeca-2(7),3,5-trιene, and 11-aza-trιcyclo[7310' ]tπdeca-2(7),3,5-tπen-5-ol, and the pharmaceutically acceptable salts and optical isomers of the foregoing compounds In a more specific embodiment the TCA analgesic agents are selected from doxepin, desipramine, tnmipramine, perphenazine, protnptyline and tranyicypromine In another more specific embodiment the anesthetic agents are selected from nitrous oxide, halothane, lidocaine, etidocaine, ropivacaine, chloro-procaine, sarapin and bupivacaine In another more specific embodiment the benzodiazepine analgesic agents are selected from diazepam, chlordiazepoxide alprazolam and lorazepam In another more specific embodiment the skeletal muscle relaxant analgesic agents are selected from flexenl, caπsoprodol, robaxisal, norgesic and dantπum In yet another more specific embodiment the migraine therapeutic agents are selected from elitπptan, sumatnptan, πzatπptan, zolmitπptan and naratπptan In yet another more specific embodiment the anticonvulsant analgesic agents are selected from gabapentin carbamazepine, topiramate, valproic acid and pregabalin In yet another more specific embodiment the opioiα analgesic agent is selected from propoxyphene, meperidine, hydro-morphone, hydrocodone, morphine, codeine and tramadol In yet another more specific embodiment the NMDA antagonists are selected from dextromethorphan, 2- pipeπdiπol -1 -alkanol derivatives as described in the United States Patent No 5,272,160, eliprodil ifenprodil In yet anotner more specific embodiment the COX 2 inhibitor analgesic agents are selected from rofecoxib and celecoxib In yet another more specific embodiment the COX 1 inhibitor analgesic agents are selected from salycylic acid, acetominophen, diclofenac baclofen piroxicam indomethacin, ibuprofen, and naproxen In yet another specific embodiment the analgesic agents are selected from clonidme, mexilitene, diphenhydramine, hydroxyzine caffeine, prednisone, methylprednisolone and decadron In yet another specific embodiment the analgesic agents are selected from fluoxetine, sertraline and paroxetine In yet another specific embodiment the analgesic agent is levodopa, Ziconotide® and substance P antagonists This invention also relates to a pharmaceutical composition for treating a disorder or condition selected from the group consisting of diseases and conditions in which pain predominates, including acute pain, chronic pain, neuropathic pain and migraine, and including soft tissue and peripheral damage, such as acute trauma, osteoarthπtis, rheumatoid arthritis, musculo- skeletal pain particularly after trauma, spinal pain, dental pain, myofascial pain syndromes, headache episiotomy pain, and burns, deep and visceral pain, such as heart pain, muscle pain eye pain orofacial pain, for example, odontalgia abdominal pain, gynaecological pain, for example dysmenorrhea, and labor pain, pain associated with nerve and root damage, such as pain associated with peripheral nerve disorders, for example, nerve entrapment and brachiai plexus avulsions amputation, peripheral neuropathies, tic douloureux atypical facial pain nerve root damage, and arachnoiditis, pain associated with carcinoma, often referred to as cancer pain, central nervous system pain, such as pain due to spinal cord or brain stem damage, low back pain, sciatica, headache, including migraine, acute or chronic tension headache cluster headache, temporomandibular pain and maxillary sinus pain ankylosing spondy tis, gout, post operative pain, and scar pain, in a mammal, including a human, the method comprising administering to said mammal respectively a pain attenuating effective amount of a pharmaceutical composition comprising (a) a nicotine receptor partial agonist or a pharmaceutically acceptable salt thereof, (b) an analgesic agent or a pharmaceutically acceptable salt thereof and (c) a pharmaceutically acceptable carrier, wherein the active agents "a" and "b" above are present in amounts that render the composition effective in treating acute, chronic and/or neuropathic pain and migraine This invention also relates to a method of treating a disorder or condition selected from the group consisting of diseases and conditions in which pain predominates, including acute pain, chronic pain, neuropathic pain and migraine, and including soft tissue and peripheral damage, such as acute trauma, osteoarthπtis, rheumatoid arthritis musculo- skeletal pain, particularly after trauma, spinal pain, dental pain, myofascial pain syndromes, headache, episiotomy pain, and burns, deep and visceral pain, such as heart pain, muscle pain, eye oaiπ, orofacial pain, for example, odontalgia, abdominal pain, gynaecological pain, for example, dysmenorrhea and labor pain, pain associated with nerve and root damage, such as pain associated with peripheral nerve disorders, for example, nerve entrapment and brachial plexus avulsions, amputation, peripheral neuropathies, tic douloureux, atypical facial pain nerve root damage, and arachnoiditis, pain associated with carcinoma, often referred to as cancer pain, central nervous system pain, such as pain due to spinal cord or brain stem damage low back pain, sciatica headache, including migraine, acute or chronic tension headache cluster headache, temporomandibular pain and maxillary sinus pain, aπkylosing spondylitis, gout, post operative pain, and scar pain, in a mammal, including a human, the method comprising administering to said mammal respectively a pain attenuating effective amount of a pharmaceutical composition comprising (a) a nicotine receptor partial agonist or a pharmaceutically acceptable salt thereof, (b) an analgesic agent or a pharmaceutically acceptable salt thereof and (c) a pharmaceutically acceptable carrier, wherein the active agents "a" and "b" above are present in amounts that render the composition effective in treating acute, chronic and/or neuropathic pain and migraine The term "treating" as used herein, refers to reversing, alleviating, inhibiting or slowing the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition The term "treatment", as used herein, refers to the act of treating, as "treating" is defined immediately above The chemist of ordinary skill will recognize that certain compounds of this invention will contain one or more atoms which may be in a particular stereochemical or geometric configuration, giving rise to stereoisomers and configurational isomers All such isomers and mixture thereof are included in tnis invention Hydrates of the compounds of this invention are also included The chemist of ordinary skill will recognize that certain combinations of heteroatom- containing substituents listed in this invention define compounds which will be less stable under physiological conditions (e g , those containing acetal or animal linkages) According, such compounds are less preferred Detailed Description of the Invention In combination with the NRPA, the invention includes an analgesic agent or a pharmaceutically acceptable salt of compounds such as opioid analgesics, NMDA antagonists, substance P antagonists, COX 1 and COX 2 inhibitors , tπcyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), capsaicin receptor agonists, anesthetic agents, benzodiazepines, skeletal muscle relaxants migraine therapeutic agents, anti- convulsants anti-hypertensives, anti-arrythmics, antihistamines, steroids, caffeine, N-type calcium channel antagonists and botuliπum toxin The herein below references refer, collectively, to quiπuclidine, pipeπdine, ethylene diamine, pyrrolidine and azanorbornane derivatives and related compounds that exhibit activity as substance P receptor antagonists and that can be used, in the pharmaceutical compositions and methods of this invention, and to methods of preparing the same United States Patent 5, 162,339, which issued on November 1 1 , 1992, United States Patent 5.232,929, which issued on August 3, 1993; World Patent Application WO 92/20676, published November 26, 1992; World Patent Application WO 93/00331 , published January 7, 1993, World Patent Application WO 92/21677, published December 10, 1992, World Patent Application WO 93/00330, published January 7, 1993; World Patent Application WO 93/06099, published April 1 , 1993, World Patent Application WO 93/10073, published May 27, 1993, World Patent Application WO 92/06079, published April 16, 1992, World Patent Application WO 92/12151 , published July 23, 1992; World Patent Application WO 92/15585 published September 17, 1992, World Patent Application WO 93/10073 published May 27, 1993 World Patent Application WO 93/19064, published September 30, 1993, World Patent Application WO 94/08997, published April 28, 1994, World Patent Application WO 94/04496, published March 3 1994, World Patent Application WO 95/07908, published March 3, 1995, World Patent Application WO 94/20500, published September 15, 1994, World Patent Application WO 94/13663, published June 23, 1994; World Patent Application WO 95/16679, published June 22, 1995, World Patent Application WO 97/08144, published March 6, 1997, World Patent Application WO 97/03066, published January 30, 1997, World Patent Application WO 99/25714, published May 27, 1999, United States Patent Application 988,653, filed December 10, 1992, United States Patent Application 026,382, filed March 4, 1993. United States Patent Application 123,306, filed September 17, 1993. and United States Patent Application 072,629, filed June 4, 1993 All of the foregoing World Patent Applications designate tne United States The foregoing patents and patent applications are incorporated herein by reference in their entirety Other substance P receptor antagonists that can be used, in the pharmaceutical compositions and methods of this invention are those compounds and pharmaceutically acceptable salts described in the following references European Patent Application EP 499,313, published August 19, 1992, European Patent Application EP 520,555, published December 30 1992, European Patent Application EP 522,808, published January 13, 1993, European Patent Application EP 528,495, published February 24, 1993, PCT Patent Application WO 93/14084, published July 22, 1993, PCT Patent Application WO 93/01 169, published January 21 , 1993, PCT Patent Application WO 93/01 165, published January 21 , 1993, PCT Patent Application WO 93/01 159, published January 21 , 1993, PCT Patent Application WO 92/20661 , published November 26, 1992, European Patent Application EP 517,589, published December 12, 1992, European Patent Application EP 428,434, published May 22, 1991 , and European Patent Application EP 360,390, published March 28, 1990, WO 94/13663 published June 23 1994 WO 97/08144 published March 6, 1997, WO 97/03066 published January 30, 1997, WO 99/125714 published May 27, 1999, WO 94/20500 published Sept, 1 5, 1994, WO 93/003300 published Jan 7 1993, and United States Provisional Patent No 60/164,692 application filed Nov 10, 1999 All of the foregoing World Patent Applications designate the United States The foregoing patents and patent applications are incorporated herein by reference in their entirety The particular NRPA compounds listed above, which can be employed in the method and pharmaceutical, compositions of this invention can be made by processes known in the chemical arts, for example by the methods described in WO 9818798 A1 , WO 9935131 -A1 and United States Provisional Patent Application No 60/083,556 filed April 29, 1998 Some of the preparation methods useful for making the compounds of this invention may require protection of remote functionality (i e , primary amine, secondary amine, carboxyl) The need for such protection will vary depending on the nature of the remote functionality and the conditions of the preparation methods The need for such protection is readily determined by one skilled in the art, and is described in examples carefully described in the above cited applications The starting materials and reagents for the NRPA compounds employed in this invention are also readily available or can be easily synthesized by those skilled in the art using conventional methods of organic synthesis Some of the compounds used herein are related to, or are derived from compounds found in nature and accordingly many such compounds are commercially available or are reported in the literature or are easily prepared from other commonly available substances by methods which are reported in the literature Some of the NRPA compounds employed in this invention are lonizable at physiological conditions Thus, for example some of the compounds of this invention are acidic and they form a salt with a pharmaceutically acceptable cation All such salts are within the scope of this mvention and they can be prepared by conventional methods For example, they can be prepared simply by contacting the acidic and basic entities, usually in a stoichiometπc ratio, in either an aqueous non-aqueous or partially aqueous medium, as appropriate The salts are recovered either by filtration, by precipitation with a non-solvent followed by filtration, by evaporation of the solvent, or, in the case of aqueous solutions, by lyophilization, as appropriate In addition, some of the NRPA compounds employed in this invention are basic, and they form a salt with a pharmaceutically acceptable anion All such salts are within the scope of this invention and they can be prepared by conventional methods For example, they can be prepared simply by contacting the acidic and basic entities, usually in a stoichiometπc ratio, in either an aqueous non-aqueous or partially aqueous medium, as appropriate The salts are recovered either by filtration, by precipitation with a non-solvent followed by filtration, by evaporation of the solvent or, in the case of aqueous solutions, by lyophilization, as appropriate In addition when the NRPA compounds employed in this invention form hydrates or solvates they are also within the scope of the invention Some of the compounds of this invention are chiral, and as such are subject to preparation via chiral synthetic routes, or separable by conventional resolution or chromatographic means All optical forms of the compounds of this invention are within the scope of the invention The utility of the NRPA compounds employed in the present invention as medicinal agents in the treatment of pain in mammals (e g humans) is demonstrated by the activity of the compounds of this invention in conventional assays and, in particular the assays described below These include neuronal nicotinic receptor binding and animal models of pain Such assays also proviαe a means whereby the activities of the compounds of this invention can be compared between themselves and with the activities of other known compounds The results of these comparisons are useful for determining dosage levels in mammals, including humans, for the treatment of such diseases Administration of the compositions of this invention can be via any method which delivers a compound of this invention systemically and/or locally These methods include oral routes and transdermal routes etc Generally, the compounds of this invention are administered orally, but parenteral administration may be utilized (e g , intravenous, intramuscular, subcutaneous or intramedullary) The two different compounds of this invention can be co-administered simultaneously or sequentially in any order, or a single pharmaceutical composition comprising a NRPA as described above and an analgesic agent as described above in a pharmaceutically acceptable carrier can be administered The amount and timing of compounds administered will, of course, be based on the judgement of the prescribing physician Thus, because of patient to patient variability, the dosages given below are a guideline and the physician may titrate doses of the agent to achieve the activity that the physician considers appropriate for the individual patient In considering the degree of activity desired, the physician must balance a variety of factors such as cognitive function, age of the patient, presence of preexisting disease, as well as presence of other diseases (e.g , cardiovascular) The following paragraphs provide preferred dosage ranges for the various components of this invention (based on average human weight of 70 kg) Biological Assays Procedures Receptor binding assay The effectiveness of the active compounds in suppressing nicotine binding to specific receptor sites is determined by the following procedure which is a modification of the methods of Lippiello P M and Ferπandes, K G (in The Binding of L- [ 3 H]Nιcotιne To A Single Class of High-Affinity Sites in Rat Brain Membranes . Molecular Pharm , 29 448-54, (1986)) and Anderson, D J and Arneric, S P (in Nicotinic Receptor Binding of 3 H-Cystιsιne, 3 H-Nιcotιne and J H-Methylcarmbamylcholιne In Rat Brain, European J Pharm , 253, 261 -67 (1994)) Male Sprague-Dawley rats (200-300 g) from Charles River were housed in groups in hanging stainless steel wire cages and were maintained on a 12 hour light/dark cycle (7 a m -7 p m light period) They received standard Purina Rat Chow and water ad libitum The rats were killed by decapitation Brains were removed immediately following decapitation Membranes were prepared from brain tissue according to the methods of Lippiello and Fernandez (Molec Pharmacol, 29, 448-454, (1986) with some modifications Whole brains were removed, rinsed with ice-cold buffer, and homogenized at 0° in 10 volumes of buffer (w/v) using a Brmkmann Polytron setting 6 for 30 seconds The buffer consisted of 50 mM Tns HCI at a pH of 7 5 at room temperature The homogenate was sedimented by centrifugation (10 minutes, 50,000 x g, 0° to 4°C) The supernatant was poured off and the membranes were gently resuspended with the Polytron and centπfuged again (10 minutes, 50,000 x g, 0 to 4°C After the second centrifugation, the membranes were resuspended in assay buffer at a concentration of 1 0g/100mL The composition of the standard assay buffer was 50 mM Tns HCI, 120 mM NaCI, 5 mM KCI, 2 mM MgCI 2 2 mM CaCI 2 and has a pH of 7 4 at room temperature Routine assays were performed in borosilicate glass test tubes The assay mixture typically consisted of 0 9 mg of membrane protein in a final incubation volume of 1 0 mL Three sets of tubes were prepared wherein the tubes in each set contained 50μL of vehicle, blank, or test compound solution, respectively To each tube was added 200μL of [ 3 H]-nιcotιne in assay buffer followed by 750μL of the membrane suspension The final concentration of nicotine in each tube was 0 9 nM The final concentration of cytisine in the blank was 1 μM The vehicle consisted of deionized water containing 30μL of 1 N acetic acid per 50 mL of water The test compounds and cytisine were dissolved in vehicle Assays were initiated by vortexing after addition of the membrane suspension to the tube The samples were incubated at 0° to 4° C in an iced shaking water bath Incubations were terminated by rapid filtration under vacuum through Whatman GF/B π,< glass fiber filters using a Brandel™ multi-manifold tissue harvester Following the initial filtration of the assay mixture, filters were washed two times with ice-cold assay buffer (5 m each) The filters were then placed in counting vials and mixed vigorously with 20 ml of Ready Safe™ (Beckman) before quantification of radioactivity Samples were counted in a LKB Wallach Rackbeta™ liquid scintillation counter at 40-50% efficiency All determinations were in triplicate Calculations Specific binding (C) to the membrane is the difference between total binding in the samples containing vehicle only and membrane (A) and non-specific binding in the samples containing the membrane and cytisine (B), i e , Specific binding = (C) = (A) - (B) Specific binding in the presence of the test compound (E) is the difference between the total binding in the presence of the test compound (D) and non-specific binding (B), ι_e., (E) = (D) - (B) % Inhibition = (1 -((E)/(C)) times 100 Tne compounds of the invention that were tested in the above assay exhibited IC 50 values of less than 10μM Assay methods for acute pain Tail flick Tail-flick testing which tests reflex nociceptive function, follows the procedure derived from D'Amour and Smith (D'Amour F E and Smith, E , A method for determining loss of pain sensation, J Pharmacol Exp Therapeutics, 72 74-79, 1941 ) The test is done with a standard apparatus obtained from Columbus instruments A beam of radiant heat from a high intensity light is focussed on the tail while the animal is manually restrained The response time is recorded, defined as the interval between the onset of the heat stimulus and the abrupt flick of the tail As soon as the response occurs, the heat is removed from the tail A cutoff time of 14 seconds (or less) is set to prevent damage to the tail of an animal with deficient sensory function The test is administered to an animal three times in a session, varying the exact location of the heat spot on the tail to minimize sensitization and potential damage Control animals have a tail fiick response latency of approximately 4 5-5 0 seconds Hot plate The hot-plate test, involving central as well as peripheral mechanisms of nociceptive responding, is conducted with an IITC model 39D Analgesia Meter A rat is placed on a surface which is maintained at 55 degrees C The surface is surrounded by a cylinder of clear plexiglass ( 10 in high) The latency between the time the rat is placed on the surface and the time it licks either hindpaw or attempts escape is the hot plate latency, and the animal is immediately removed from the apparatus at this time One determination is recorded To prevent tissue damage, tests of non-responsive animals are terminated after 40 sec , with that time assigned as the response latency During the week prior to testing, the rats are given brief exposures to the non-functional hot-plate to adapt them to the testing situation Control animals respond between 10-15 seconds Assay method for acute and chronic pain Formalin test This test does not allow escape from the stimulus, but is established as a standard means to test responses to a longer-duration nociceptive chemical stimulus The response has two phases that appear to have separate mechanisms, distinct from one another and from the responses tested using the tests listed above, that can be independently investigated only by use of this test or similar tests (see (Tjolsen et al , 1992, cited below) Animals are adapted to the testing situation without formalin injection during the week before the test Fifty ml of 5% formalin solution is injected subcutaneously into the dorsal surface of the right hind paw with a 30 guage needle The rat is then placed in an open plexiglass chamber to allow unhindered observation of the formalin-injected paw Nociception-related behavior is quantified by counting the incidence of spontaneous flinching or shaking of the injected paw Flinches are counted for each individual animal in periods of 1 minute starting at 1 -2 mm after formalin injection, then at 5-mιnute intervals during the interval from 10-60 minutes After the observation period of 1 hour animals are sacrificed Previous studies report that the duration of the painful stimulus in the formalin test is limited, and beyond one hour the pain is minimal (for review see Tjolsen, A , Berge, O-G., Hunskaar, S , Rosland, J H , and Hole, K , The formalin test an evaluation of the method, Pain, 51 '5-17, 1992) Assay method for neuropathic pain Recently, several animal models of neuropathic pain have been developed in rats Bennett Model [G J Bennett Pain, 33, 87-107, 1988] Under anesthesia, the rat is placed in a prone position and an incision is made in the skin over the thigh The fascia between the gluteus and biceps femoπs muscle is dissected and the right common sciatic nerve is exposed at the level of the midthigh Proximal to its trifurcation, the nerve is carefully dissected from its surrounding tissue over a distance of about 8 mm In the experimental group, ligatures are loosely tied around the common sciatic nerve A similar dissection is performed on the contralateral side, except that the nerve is not ligated (sham surgery) A group of control animals with bilateral sham surgery is also included Comparison of the results of the experimental and control sides of the experimental rats allows the detection of possible contralateral effects of the nerve hgation In general, an effective dosage for the NRPA in the range of 0 001 to 200 mg/kg/day, prererably 0 001 to 10 0 mg/kg/day lr particular, an effective dosage for propoxyphene when used in the combination comDositions and methods of this invention, is in the range of 0 1 to 5 7 mg/kg/day In particular, an effective dosage for meperidine, when used in the combination compositions and methods of this invention, is in the range of 0 1 to 2 0 mg/kg/day In particular, an effective dosage for hydromorphone, when used in the combination comoositions and methods of this invention, is in the range of 0 01 to 0 2 mg/kg/day In particular, an effective dosage for hydrocodone, when used in the combination compositions and methods of this invention, is in the range of 0 04 to 0 6 mg/kg/day In particular, an effective dosage for morphine, when used in the combination compositions and methods of this invention, is in the range of 0 1 to 4 0 mg/kg/day In particular, an effective dosage for codeine, when used in the combination compositions and methods of this invention, is in the range of 0 01 to 0 3 mg/kg/day In particular, an effective dosage for 2-pιperιdιnol-1 -alkanol derivatives as described in United States Patent No 5, 272 160, when used in the combination compositions and methods of this invention, is in the range of 0 1 to 20 mg/kg/day In particular, an effective dosage for eliprodil, when used in the combination compositions and methods of tnis invention, is in the range of 0 01 to 0 4 mg/kg/day In particular an effective dosage for ifenprodil when used in the combination compositions and methods of this invention, is in the range of 0 01 to 0 3 mg/kg/day In particular, an effective dosage for rofecoxib, when used in the combination compositions and methods of this invention, is in the range of 0 1 to 0 35 mg/kg/day In particular, an effective αosage for celecoxib, when used in the combination compositions and methods of this invention is in the range of 1 0 to 5 7 mg/kg/day In particular, an effective dosage for salycylic acid (aspirin), when used in the combination compositions and methods of this invention, is in the range of 1 0 to 50 0 mg/kg/day In particular an effective dosage for diclofenac, when used in the combination compositions and methods of this invention is in the range of 0 1 to 3 0 mg/kg/day In particular, an effective dosage for piroxicam, when used in the combination compositions and methods of this invention, is in the range of 0 1 to 0 3 mg/kg/day In particular an effective dosage for indomethacin, when used in the combination compositions and methods of this invention is in the range of 0 1 to 1 0 mg/kg/day In particular, an effective dosage for ibuprofen, when used in the combination compositions ana methods of this invention, is in the range of 1 0 to 15 0 mg/kg/day In particular, an effective dosage for naproxen, when used in the combination compositions and methods of this invention, is in the range of 1 0 to 15 0 mg/kg/day In particular, an effective dosage for gabapentin, when used in the combination compositions and methods of this invention is in the range of 10 0 to 35 0 mg/kg/day In particular, an effective dosage for carbemazepine, when used in the combination compositions and methods of this invention, is in the range of 1 0 to 20 0 mg/kg/day In particular, an effective dosage for pregabalin, when used in the combination compositions and methods of this invention, is in the range of 1 0 to 10 0 mg/kg/day In particular, an effective dosage for topiramate when used in the combination compositions and methods of this invention, is in the range of 0 1 to 6 0 mg/kg/day In particular, an effective dosage for valproic acid, when used in the combination compositions and methods of this invention, is in the range of 1 0 to 60 mg/kg/day In particular, an effective dosage for sumatnptan, when used in the combination compositions and methods of this invention, is in the range of 0 1 to 1 5 mg/kg/day In particular, an effective dosage for elitnptan, when used in the combination compositions and methods of this invention, is in the range of 0 1 to 1 1 mg/kg/day In particular, an effective dosage for πzatriptan, when used in the combination compositions and methods of this invention, is in the range of 0 05 to 0 15 mg/kg/day In particular, an effective dosage for zolmitπptan when used in the combination compositions and methods of this invention, is in the range of 0 01 to 0 1 mg/kg/day In particular, an effective dosage for naratπptan, when used in the combination compositions and methods of this invention, is in the range of 0 01 to 0 07 mg/kg/day In particular, an effective dosage for flexeπl, when used in the combination compositions and methods of this invention is in the range of 0 1 to 0 9 mg/kg/day In particular, an effective dosage for caπsoprodol, when used in the combination compositions and methods of this invention, is in the range of 1 0 to 20 0 mg/kg/day In particular, an effective dosage for robaxisal, when used in the combination compositions and methods of this invention, is in the range of 1 0 to 70 0 mg/kg/day In particular an effective dosage for norgesic when used in the combination compositions and methods of this invention, is in the range of 0 1 to 1 5 mg/kg/day In particular, an effective dosage for dantπum, when used in the combination compositions and methods of this invention, is in the range of 0 1 to 1 0 mg/kg/day In particular an effective dosage for diazepam, when used in the combination comoositions and methods of this invention is in the range of 0 01 to 0 5 mg/kg/day In particular, an effective dosage for chlordiazepoxide, when used in the combination compositions and methods of this invention is in the range of 0 05 to 1 4 mg/kg/day In particular an effective dosage for alprazolam, when used in the combination compositions and methods of this invention, is in the range of 0 001 to 0 05 mg/kg/day In particular an effective dosage for lorazepam, when used in the combination compositions and methods of this invention, is in the range of 0 005 to 0 15 mg/kg/day In particular an effective dosage for acetominophen, when used in the combination compositions and methods of this invention, is in the range of 1 0 to 5 0 mg/kg/day In particular, an effective αosage for nitrous oxide, when used in the combination compositions and methods of this invention is in the range of 10% to 50% mg/kg/day In particular an effective dosage for halothane, when used in the combination compositions and methods of this invention, is in the range of 0 1 % to 3 0% In particular, an effective dosage for lidocaine, when used in the combination compositions and methods of this invention is in the range of 0 1 % to 2 0% In particular, an effective dosage for etidocaine when used in the combination compositions and methods of this invention is in the range of 0 1 % to 1 5% In particular, an effective dosage for ropivacaine, when used in the combination compositions and methods of this invention, is in the range of 0 1 % to 1 0% In particular an effective dosage for chloroprocaine, when used in the combination compositions and methods of this invention, is in the range of 0 1 % to 2 0% mg/kg/day In particular an effective dosage for sarapin when used in the combination compositions and methods of this invention is in the range of 0 1 to 10 mis of a sterile aqueous solution of soluble salts of the volatile bases from Sarraceniaceae (Pitcher Plant) In particular, an effective αosage for bupivacaine, when used in the combination compositions and methods of this invention is in the range of 0 1 % to 0 75% In particular, an effective dosage for capsaicin receptor agonists such as Arthπcare, when used in the combination compositions and methods of this invention, is in the range of 0 01 % to 0 1 % In particular, an effective dosage for desipramine, when used in the combination compositions and methods of this invention is in the range of 0 1 to 3 0 mg/kg/day In particular, an effective dosage for amitnptyline, when used in the combination compositions and methods of this invention, is in the range of 0 1 to 2 0 mg/kg/day In particular, an effective dosage for doxepin, when used in the combination compositions and methods of this invention, is in the range of 0 1 to 2 0 mg/kg/day In particular, an effective dosage for perphenazine, when used in the combination compositions and methods of this invention, is in the range of 0 01 to 0 2 mg/kg/day In particular, an effective dosage for protnptyline, when used in the combination compositions and methods of this invention, is in the range of 0 05 to 0 9 mg/kg/day In particular, an effective dosage for tranyicypromine, when used in the combination compositions and methods of this invention, is in the range of 0 1 to 0 9 mg/kg/day In particular an effective dosage for baclofen, when used in the combination compositions and methods of this invention, is in the range of 0 1 to 0 5 mg/kg/day In particular, an effective dosage for clonidine, when used in the combination compositions and methods of this invention, is in the range of 0 001 to 0 03 mg/kg/day In particular, an effective dosage for mexelitine, when used in the combination compositions and methods of this invention, is in the range of 1 0 to 15 0 mg/kg/day In particular an effective dosage for diphenhydramine, when used in the combination compositions and methods of this invention, is in the range of 0 1 to 4 0 mg/kg/day In particular, an effective dosage for hydroxyzine, when used in the combination compositions and methods of this invention, is in the range of 0 1 to 5 0 mg/kg/day In particular, an effective dosage for caffeine, when used in the combination compositions and methods of this invention, is in the range of 0 1 to 15 0 mg/kg/day In particular, an effective dosage for prednisone, when used in the combination compositions and methods of this invention, is in the range of 0 01 to 1 0 mg/kg/day In particular, an effective dosage for methyl-predinsone, when used in the combination compositions and methods of this invention, is in the range of 0 01 to 0 5 mg/kg/day In particular, an effective dosage for decadron, when used in the combination compositions and methods of this invention, is in the range of 0 005 to 0 1 mg/kg/day In particular, an effective dosage for sertra ne, when used in the combination compositions and methods of this invention, is in the range of 0 1 to 3 0 mg/kg/day In particular, an effective dosage for paroxetine, when used in the combination compositions and methods of this invention, is in the range of 0 1 to 0 7 mg/kg/day In particular, an effective dosage for fluoxetine when used in combination composition and methods of this invention is in the range of 0 1 to 1 0 mg/kg/day In particular, an effective dosage for tramodol, when used in the combination compositions and methods of this invention, is in the range of 0 5 to 5 0 mg/kg/day In particular, an effective dosage for levodopa, when used in the combination compositions and methods of this invention, is in the range of 1 0 to 15 0 mg/kg/day In particular, an effective dosage for dextromethorphan, when used in the combination compositions and methods of this invention, is in the range of 0 1 to 1 5 mg/kg/day In particular, an effective dosage for substance P antagonists, when used in the combination compositions and methods of this invention, is in the range of 0 01 to 15 0 mg/kg/day In particular, an effective dosage for Ziconotide®, when used in combination compositions and methods of this invention, is in the range of 0 1 to 1 0 mg/kg/day In particular, an effective dosage for botulmum toxin, when used in the combination compositions and methods of this invention, is in the range of 1 to 10 units/day The compositions of the present invention are generally administered in the form of a pharmaceutical composition comprising at least one of the compounds of this invention together with a pharmaceutically acceptable vehicle or diluent Thus, the compounds of this invention can be administered individually or together in any conventional oral, parenteral or transdermal dosage form For oral administration a pharmaceutical composition can take the form of solutions, suspensions tablets, pills capsules, powders, and the like Tablets containing various excipient such as sodium citrate, calcium carbonate and calcium phosphate are employed along with various disintegrants such as starch and preferably potato or tapioca starch and certain complex silicates, together with binding agents such as polyvinylpyrrohdone, sucrose, gelatin and acacia Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes Solid compositions of a similar type are also employed as fillers in soft and hard-filled gelatin capsules, preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols When aqueous suspensions and/or elixirs are desired for oral administration, the compounds of tnis invention can be combined with various sweetening agents, flavoring agents, coloring agents, emulsifying agents and/or suspending agents, as well as such diluents as water, ethanol, propylene glycol glycerin and various like combinations thereof For purposes of parenteral administration, solutions in sesame or peanut oil or in aqueous propylene glycol can be employed as well as sterile aqueous solutions of the corresponding water-soluble salts Such aqueous solutions may be suitably buffered, if necessary, and the liquid diluen * first rendered isotonic with sufficient saline or glucose These aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intrapentoneal injection purposes In this connection, the sterile aqueous media employed are all readily obtainable by standard techniques well-known to those skilled in the art For purposes of transdermal (e g .topical) administration, dilute sterile, aqueous or partially aqueous solutions (usually in about 0 1 % to 5% concentration), otherwise similar to the above parenteral solutions, are prepared Methods of preparing various pharmaceutical compositions with a certain amount of active ingredient are known, or will be apparent in light of this disclosure, to those skilled in this art For examples, see Remington's Pharmaceutical Sciences , Mack Publishing Company, Easter, Pa , 15th Edition (1975) Pharmaceutical compositions according to the invention may contain 0 1 %-95% of the compound(s) of this invention, preferably 1 %-70% In any event, the composition or formulation to be administered will contain a quantity of a compound(s) according to the invention in an amount effective to treat the pain of the subject being treated

Claims: Claims 1 A pharmaceutical composition for the treatment of acute, chronic and/or neuropathic pain and migraine comprising (a) a nicotine receptor partial agonist or a pharmaceutically acceptable salt thereof, (b) an analgesic agent or pharmaceutically acceptable salt thereof and (c) a pharmaceutically acceptable carrier, wherein the active agents ' a" and "b" above are present in amounts that render the composition effective in treating acute chronic and/or neuropathic pain, and migraine 2 The pharmaceutical composition according to Claim 1 , wherein said analgesic agent is selected from opioid analgesics, NMDA antagonists, substance P antagonists COX 1 and COX 2 inhibitors , tπcyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI) capsaicin receptor agonists, anesthetic agents, benzodiazepines, skeletal muscle relaxants migraine therapeutic agents, anti-convulsants, anti-hypertensives, anti-arrythmics, antihistamines steroids, caffeine, N-type calcium channel antagonists, and botu num toxin 3 The pharmaceutical composition according to Claim 2, wherein said opioid analgesic agent is selected from propoxyphene (Darvon), meperidine (Demerol), hydromorphone (Dilaudid), hydrocodone (Lortab), morphine, codeine and tramodol, their pharmaceutically active salts and their optical isomers 4 The pharmaceutical composition according to Claim 2 wherein said NMDA antagonist analgesic agent is selected from 2-pιperdιno-1 alkanol deπvates, dextromethorphan, eliprodil, and ifenprodil, their pharmaceutically active salts and their optical isomers 5 The pharmaceutical composition according to Claim 2, wherein the substance P antagonist analgesic agent is selected from (6-Methoxy-3-trιfluoromethvl-benzo[d]ιsoxazol-5-ylmethyl)-(2-phenyl-pιperιdιn-3-yl)- amine, 6-Methoxy-1 -methyl-7-[(2-phenyl-1 -propyl-pιpeπdιn-3-ylamιno)-methyl]-3,4-dιhydro- 1 H-quιnolιn-2-one, 6-Methoxy-1 -methyl-7-{[1 -(5-0X0-2, 5-dιhydro-1 H-[1 ,2,4]trιazol-3-ylmethyl)-2-phenyl- pιperιdιn-3-ylamιno]-methyl}-3,4-dιhydro-1 H-quιnoiιn-2-one, 3-(2-Methoxy-5-tπfluoromethoxy-phenyl)-6-phenyl-1 ,7-dιaza-spιro[4 5]decane, 6-Methoxy-1 -methyl-7-[(2-phenyl-pιperιdιn-3-ylamιno)-methyl]-3,4-dιhydro-1 H- quιnolιn-2-one, [2-Methoxy-5-(2,2 2-trιfluoro-1 -tπfluoromethyl-ethyl)-benzyl]-(2-phenyl-pιpeπdιn-3-yl)- amine, [5-(1 ,1 -Dιmethyl-prop-2-ynyl)-2-methoxy-benzyl]-(2-phenyl-pιpeπdιn-3-yl)-amιne, 7-Methoxy-1 -methyl-6-[(2-phenyl-pιpeπdιn-3-ylamιno)-methyl]-3,4-dιhydro-1 H- quιnolιn-2-one, [2-Methoxy-5-(2,2,2-tπfluoro-1 , 1 -dimethyl-ethyl )-benzyl]-(2-phenyl-pιpeπdιn-3-yl)- amine, (7-Methoxy-4-methyl-3 4-dιhydro-2H-benzo[1 ,4]oxazιn-6-ylmethyl)-(2-phenyl- pιpeπdιn-3-yl)-amιne, [2-Methoxy-5-(1 -methyl-1 -tπfluoromethyl-prop-2-ynyl)-benzyl]-(2-phenyl-pιperιdιn-3- yl)-amιne (6-Methoxy-1 -methyl-1 -tπfluoromethyl-ιsochroman-7-ylmethyl)-(2-phenyl-pιpeπdιn-3- yl)-amιne, 2-{3-[(2-Benzhydryl-1 -aza-bιcyclo[2 2 2]oct-3-ylamιno)-methyl]-4- mefhoxy-phenyl}-2- methyl-propan-1 -ol, (2S 3S)-N-[(5-oxo-1 H.4H-1 ,2,4-tπazolo)methyl]-2-(4-fluorophenyl)-3-(3,5- dιtπfluoromefhyl)benzyloxymorpholιne, 3-(3,5-Bιs-tπfluoromethyl-benzyloxy)-2-phenyi-pιperιdιne, 5-[2-(3,5-Bιs-trιfluoromethyl-benzyloxy)-3-phenyl-morpholιn-4-ylmethyl]-2,4-dιhydro- [1 ,2,4]tπazol-3-one, (2S, 3S)-3-(2-Methoxy-5-(tπfluoromethoxy)benzyl)amιno-2-phenylpιperιdιne, (2S 3S)-N-(5-ιsopropyl-2-methoxyphenyl)methyl-2-dιphenylmethyl-1 - azabιcyclo[2 2 2]-octan-3-amιne, (2S, 3S)-N-(5-tert-butyl-2-methoxyphenyl)methyl-2-dιphenylmethyl-1 - azabιcyclo[2 2 2]-octane-3-amιne, (2S, 3S)-N-(5-ethyl-2-methoxyphenyl)methyl-2-dιphenylmethyl-1 -azabιcyclo[2.2.2]- octan-3-amιne, and (2S,3S)-N-(5-n-propyl-2-methoxyphenyl)methyl-2-dιphenylmethyl-1 -azabιcyclo[2.2 2]- octane-3-amιne, their pharmaceutically active salts and their optical isomers 6 The pharmaceutical composition according to Claim 2 wherein the COX 2 inhibitor analgesic agent is selected from rofecoxib and celecoxib their pharmaceutically active salts and their optical isomers 7 The pharmaceutical composition according to Claim 2 wherein the anesthetic analgesic agent agent is selected from nitrous oxide halothane, lidocaine, etidocaine, ropivacaine, chloroprocaine, sarapin and bupivacaine their pharmaceutically active salts and their optical isomers 8 The pharmaceutical composition according to Claim 2 wherein the benzodiazepine analgesic agent is selected from diazepam, chlordiazepoxide, alprazolam, and lorazepam their pharmaceutically active salts and their optical isomers 9 The pharmaceutical composition according to Claim 2 wherein the skeletal muscle relaxant analgesic agent is selected from flexeπl, caπsoprodol, robaxisal, norgesic and dantπum their pharmaceutically active salts and their optical isomers 10 The pharmaceutical composition according to Claim 2 wherein the migraine therapeutic agent is selected from elitnptan, sumatπptan, πzatπptan, zolmitπptan, and naratπptan their pharmaceutically active salts and their optical isomers 1 1 The pharmaceutical composition according to Claim 2 wherein the anticonvulsant analgesic agent is selected from gabapentin, pregabalin, carbamazepine, and topiramate and valproic acid their pharmaceutically active salts and their optical isomers 12 The pharmaceutical composition according to Claim 2 wherein the COX 1 inhibitor analgesic agent is selected from salycylic acid, acetominophen, diclofenac, piroxican indomethacin ibuprofen, and naproxen their pharmaceutically active salts and their optical isomers 13 The pharmaceutical composition according to Claim 2 wherein the tncyclic antidepressant analgesic agent is selected from amitnptyline desipramine, perphenazine, protnptyline, and tranyicypromine their pharmaceutically active salts and their optical isomers 14 The pharmaceutical composition according to Claim 1 wherein the analgesic agent is chosen from baclofen, clonidine, mexilitene, diphenyl-hydramine, hydroxysine, caffeine, prednisone, methylprednisone decadron, paroxetme, sertra ne, fluoxetine, tramodol, Ziconotide© and levoαopa their pharmaceutically active salts and their optical isomers 15 The pharmaceutically composition according to Claim 1 , wherein said nicotine receptor partial agonist is selected from 9-bromo-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-chloro-1 ,2 3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-fluoro-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-ethyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-mefhyi-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-phenyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-vιnyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-bromo-3-methyl-1 ,2,3,4,5 6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8- one, 3-benzyl-9-bromo-1 ,2 3,4,5,6-hexahydro-1 .5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8- one, 3-benzyl-9-chloro-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8- one, 9-acetyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-ιodo-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-cyano-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-ethynyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-(2-propenyl)-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-(2-propyl)- 1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-carbomethoxy-1 ,2,3 4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-carboxyaldehyde-1 ,2,3 4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-(2,6-dιfluorophenyl)-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 .2a][1 ,5]dιazocιn-8- one, 9-phenyl-1 ,2 3,4.5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-(2-fluorophenyl)-1 ,2.3 4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-(4-fluorophenyl)-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-(3-fluorophenyl)-1 ,2,3 4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-(3 5-dιfluorophenyl)-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-(2,4-dιfluorophenyl)-1 ,2.3,4,5.6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-(2,5-dιfluorophenyl)-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8- one, 6-methyl-5-oxo-6, 13-dιazatetracyclo[9 3 1 0 2 10 0 4 8 ]pentadeca-2( 10),3.8-tπene, 5-0x0-6, 13-dιazatetracyclo[9 3 1 0 2 10 0 4 8 ]pentadeca-2(10),3,8-trιene, 6-0X0-5,7, 13-trιazatetracyclo[9 3 1 0 2 10 0 4 8 ]pentadeca-2(10),3,8-trιene, 4,5-dιfluoro-10-aza-tπcyclo[6 3 1 0 2 7 ]dodeca-2(7),3,5-tπene, 5-fluoro-10-aza-tπcyclo[6 3 1 O 2 ']dodeca-2(7),3,5-trιene-4-carbonιtπle, 4-ethynyl-5-fluoro-10-aza-tπcyclo[6 3 1 0 2 7 ]dodeca-2(7),3,5-trιene, 5-ethynyl-10-aza-tπcyclo[6 3 1 0^ ']dodeca-2(7),3,5-tπene-4-carbonιtπle, 6-methyl-5-thιa-5-dιoxa-6 13-dιazatetracyclo[9 3 1 0 2 10 0 4 8 ]pentadeca-2(10),3,8- tπeπe, 10-aza-trιcyclo[6 3 1 0- ]dodeca-2(7),3,5-tπene, 4-fluoro-10-aza-trιcyclo[6 3 1 0 2 7 ]dodeca-2(7),3,5-trιene, 4-methyl-10-aza-tπcyclo[6 3 1 0 2 ']dodeca-2(7),3,5-tπene, 4-tπfluoromethyl-10-aza-tπcyclo[6310 27 ]dodeca-2(7),3,5-trιene, 4-nιtro-10-azatπcyclo[6310 27 ]dodeca-2(7),3,5-trιeπe, 7-methyi-5J,13-tπazatetracyclo[9310 210 0 48 ]pentadeca-2(10),3,5.8-tetraene, 6-methyl-57,13-trιazatetracyclo[9310 210 0 8 ]pentadeca-2(10),3,58-tetraene, 67-dιmethyl-5,713-tπazatetracyclo[9310 210 0 48 ]pentadeca-2(10), 3, 5, 8-tetraene, 6-methyl-7-phenyl-5,7,13-trιazatetracyclo[931 O 210 0 48 ]pentadeca-2(10),3,5,8- tetraene 6,7-dιmethyl-5814-tπazatetracyclo[10310 211 0 49 ]hexadeca-2(11),3,5,7,9-pentaene, 5814-tπazatetracyclo[10310 211 0 49 ]hexadeca-2(11), 3, 5, 7, 9-pentaene, 14-methyl-5,814-tπazatetracyclo[10310 211 0 49 ]hexadeca-2(11), 3, 5, 7, 9-pentaene, 5-oxa-713-dιazatetracyclo[931 O 210 0 48 ]pentadeca-2(10),3, 6, 8-tetraene, 6-methyl-5-oxa-7,13-dιazatetracyclo[9310 210 0 4δ ]pentadeca-2(10),3,6, 8-tetraene, 4-chloro-10-azatncyclo[6310 27 ]dodeca-2(7),3,5-tπene, 10-azatπcyclo[6310' ]dodeca-2(7),3,5-trιen-4-yl cyanide, 1 -(10-azatπcyclo[6310 2 ~]dodeca-2(7),3,5-trιen-4-yl)-1 -ethanone, 10-azatπcyclo[6310 2" ]αodeca-2(7),3,5-tπen-4-ol, 7-methyl-5-oxa-6,13-dιazatetracyclo[9310 21C 0 48 ]pentadeca-2,4(8),6,9-tetraene, 4,5-dιchloro-10-azatπcyclo[6310 27 ]dodeca-2(7),3,5-trιene, 11-azatrιcyclo[7310' ]tπdeca-2(7),3,5-tπene-5-carbonιtπle, 1 -[11 -azatπcyclo[7310 2 " ]tndeca-2(7),3,5-tnen-5-yl]-1 -ethanone, 1-[11-azatrιcyclo[7310 2 ]tπdeca-2(7) 3,5-tπen-5-yl]-1-propanone, 4-fluoro-11-azatπcyclo[7310 2 ]trιdeca-2(7) 3,5-tπene-5-carbonιtrιle, 5-fluoro-11-azatπcyclo[7310 2 ']tπdeca-2(7),3,5-trιene-4-carbonιtrιle, 6-methyl-7-thιa-514-dιazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3,5,8-tetraene, 6-methyl-5714-tnazatetracyclo[10310 210 0 48 ]hexadeca-2(10), 3, 5, 8-tetraene, 6,7-dιmethyl-5,7,14-trιazatetracyclo[10310 210 0 4δ ]hexadeca-2(10), 3, 5, 8-tetraene, 5,7,14-tπazatetracyclopO 310 210 0 48 ]hexadeca-2(10),3,5,8-tetraene, 5,6-dιmethyl-57,14-trιazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3,6, 8-tetraene, 5-methyl-5,7,14-tπazatetracyclo[1031 O 210 0 48 ]hexadeca-2( 10), 3, 6,8-tetraene, 6-(trιfluoromethyl)-7-thιa-514-dιazatetracyclo[10310 210 O 48 ]hexadeca-2(10),3,5,8- tetraene, 5,815-tπazatetracyclo[11310 21 0 49 ]heptadeca-2(11), 3, 5, 7, 9-pentaene, 7-methyl-5,8,15-tπazatetracyclo[1131 O 2 " 1 0 49 ]heptadeca-2(11),3, 57, 9-pentaene, 6-methyl-5,8,15-tπazatetracyclo[11310 2 1 0 49 ]heptadeca-2(11),3,5,7,9-pentaene, 6J-dιmethyl-58,15-tπazatetracyclo[11310 211 0 49 ]heptadeca-2(11),3, 5,7,9- pentaene, 7-oxa-5,14-dιazatetracyclo[10310 210 0 8 ]hexadeca-2(10),3,5,8-tetraene, 6-methyl-7-oxa-5,14-dιazatetracyclo[10310 210 0 8 ]hexadeca-2(10),3,5,8-tetraene, 5-methyl-7-oxa-6,14-dιazatetracyclo[10310 210 0 8 ]hexadeca-2(10),3,5,8-tetraene, 6-methyl-5-oxa-7,14-dιazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3, 6, 8-tetraene, 7-methyl-5-oxa-6,14-dιazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3, 6,8-tetraene, 45-dιfluoro-11-azatπcyclo[7310 27 ]tπdeca-2(7),3,5-tπene, 4-chioro-5-fluoro-11-azatπcyclo[7310 2 ']tπdeca-2(7),3,5-trιene, 5-chloro-4-fiuoro-11-azatrιcyclo[7310 27 ]tπdeca-2(7),3,5-tπene, 4-(1-ethynyl)-5-fluoro-11-azatπcyclof7310 27 ]tπdeca-2(7),3,5-trιene, 5-(1-ethynyl)-4-fluoro-11-azatrιcyclo[7310 27 ]tπdeca-2(7),3,5-tπene, 56-dιfluoro-11-aza-tπcyclo[7310 27 ]trιdeca-2,46-trιene, 6-tπfluoromethyl-11-aza-tπcyclo[7310 2 ']tπdeca-2,4,6-tπene, 6-methoxy-11-aza-tπcyclo[7310 2 ']tπdeca-2(7) 3,5-tπene, 11-aza-trιcyclo[7310 27 ]tπdeca-2(7),3,5-trιen-6-ol, 6-fluoro-11 -aza-trιcyclo[7310 27 ]trιdeca-2(7),35-tπene, 11-aza-tπcyclo[7310 2 ~]tπdeca-2(7),35-trιen-5-ol 4-nιtro-11-aza-trιcyclo[7310 27 ]tπdeca-2(7),3,5-tπene, 5-nιtro-11-aza-trιcyclo[7310 27 ]tπdeca-2(7),3,5-trιene, 5-fluoro-11-aza-trιcyclo[7310 27 ]trιdeca-2(7),3.5-tπene, 6-hydroxy-5-methoxy-11-aza-trιcyclo[7310 27 ]trιdeca-2(7),3,5-trιene, and their pharmaceutically acceptable salts and their optical isomers 16 The pharmaceutical composition according to Claim 16 wherein said nicotine receptor partial agonist is selected from 9-bromo-1 ,2,3,4,5,6-hexahydro-15-methano-pyrιdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-chloro-1,2,34.5,6-hexahydro-15-methano-pyπdo[1,2-a][1,5]dιazocιn-8-one, 9-fluoro-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-acetyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-ιodo-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-cyano-1 ,2,3,4,5,6-hexahydro-15-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-carbomethoxy-1 ,234,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-carboxyaldehyde-123456-hexahydro-1,5-methano-pyπdo[1,2a][1,5]dιazocιn-8- one, 9-(2,6-dιfluorophenyl)-12345,6-hexahydro-1,5-methano-pyrιdo[1,2a][1,5]dιazocιn-8- one, 9-phenyl-12,3,4,56-hexahydro-15-methano-pyrιdo[1,2a][1,5]dιazocιn-8-one, 9-(2-fluorophenyl)-1 ,234,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8- one, 6-methyl-5-thιa-5-dιoxa-613-dιazatetracyclo[9310 210 0 8 ]pentadeca-2(10),3,8- triene, 4-fluoro-10-aza-trιcyclo[6310 7 ]dodeca-2(7),3,5-tπene 4-trιfluoromethyl-10-aza-tπcyclo[6310 27 ]dodeca-2(7),3,5-trιene, 4-nιtro-10-azatrιcyclo[6310 27 ]dodeca-2(7),3,5-tπene, 6-methyl-5,7,13-tπazatetracyclo[9310 210 0 48 ]pentadeca-2(10),35,8-tetraene, 6,7-dιmethyl-5,814-tπazatetracyclo[10310 211 0 49 ]hexadeca-2(11), 3, 5, 7, 9-pentaene, 5,814-tπazatetracyclo[10310 2 0 49 ]hexadeca-2(11),3,5,7,9-pentaene, 5-oxa-7,13-dιazatetracyclo[9310 210 0 48 ]pentadeca-2(10), 3,6, 8-tetraene, 6-methyl-5-oxa-7,13-dιazatetracyclo[9310 210 0 48 ]pentadeca-2(10), 3, 6, 8-tetraene, 10-azatπcyclo[6310 2" ]dodeca-2(7),3,5-tπen-4-yl cyanide, 1-(10-azatπcyclo[6310 2~ ]dodeca-2(7),3,5-trιen-4-yl)-1-ethanone, 11-azatrιcyclo[7310 2 ]tπdeca-2(7),3,5-trιene-5-carbonιtrιle, 1-[11-azatrιcyclo[7310 2' ]tπdeca-2(7),3,5-tπen-5-yl]-1-ethanone, 1-[11-azatπcyclo[7310 2 ']trιdeca-2(7),35-tπen-5-yl]-1-propanone, 4-fluoro-11-azatπcyclo[7310 2 ]tπdeca-2(7),3,5-trιene-5-carbonιtrιle, 5-fluoro-11-azatrιcyclo[7310 2 ']tπdeca-2(7),3,5-trιene-4-carbonιtπle, 6-methyl-7-thιa-514-dιazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3,5.8-tetraene, 6-methyl-5J,14-tπazatetracyclo[10310 210 0 48 ]hexadeca-2{10),3, 5,8-tetraene, 67-dιmethyl-5,714-tπazatetracyclo[10310 210 0 48 ]hexadeca-2(10), 3, 5,8-tetraene, 6-methyl-7-oxa-5,14-dιazatetracyclo[10310 210 0 48 ]hexadeca-2(10), 3, 5,8-tetraene, 6-methyl-5-oxa-714-dιazatetracyclo[10310 210 0 48 ]hexadeca-2(10), 3, 6,8-tetraene, 56-dιfluoro-11 -aza-tπcyclo[7310 2 ^ ]tπdeca-24,6-trιene, 6-tπfluoromethyl-11-aza-tπcyclo[7310 27 ]tπdeca-2,4,6-trιene, 6-methoxy-11-aza-tπcyclo[7310 2 ]trιdeca-2(7),3,5-tπene, 6-fluoro-11-aza-tπcyclo[7310 2" ]trιdeca-2(7),3,5-trιene, 11-aza-tπcyclo[7310' ]tπdeca-2(7),3,5-trιen-5-ol, and their pharmaceutically acceptable salts and their optical isomers thereof 17 A method of treating acute, chronic and/or neuropathic pain and migraine in a mammal comprising administering to said mammal, respectively a pain attenuating effective amount of a pharmaceutical composition comprising (a) a nicotine receptor partial agonist or a pharmaceutically acceptable salt thereof, (b) an analgesic agent or pharmaceutically acceptable salt thereof and (c) a pharmaceutically acceptable carπes, wherein the active agents "a" and "b" above are present in amounts that render the composition effective in treating acute chronic and/or neuropathic pain and migraine 18 The method according to claim 17 wherein the analgesics are selected from opioid analgesics, NMDA antagonists, substance P antagonists, COX 1 and COX 2 inhibitors, tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRl), capsaicin receptor agonists, anesthetic agents, benzodiazepines, skeletal muscle relaxants, migraine therapeutic agents, anti-convulsants anti-hypertensives, anti-arrythmics, antihistamines, steroids, caffeine N-type calcium channel antoginists and botulinum toxin or their pharmaceutically acceptable salt or optical isomers 19 The method according to claim 18 wherein said NMDA antagonist analgesic agent is selected from 2-pιpeπdιnol-1 alkanol derivatives, dextromethorphan, eliprodil, and ifenprodil their pharmaceutically active salts and their optical isomers 20 The method according to claim 18 wherein the substance P antagonists are selected from (6-Methoxy-3-tπfluoromethyl-benzo[d]ιsoxazol-5-ylmethyl)-(2-phenyl-pιpeπdιn-3-yl)- amine 6-Methoxy-1 -methyl-7-[(2-phenyl-1 -propyl-pιpeπdιn-3-ylamιno)-methyl]-3,4-dιhydro- 1 H-quιnolιn-2-one, 6-Methoxy-1 -methyl-7-{[1 -(5-oxo-2,5-dιhydro-1 H-[1 ,2 4]trιazol-3-ylmethyl)-2-phenyl- pιperιdιn-3-ylamιno]-methyl}-3 4-dιhydro-1 H-quιπolιn-2-oπe, 3-(2-Methoxy-5-tπfluoromethoxy-phenyl)-6-phenyl-1 7-dιaza-spιro[4 5]decane, 6-Methoxy-1 -methyl-7-[(2-phenyl-pιperιdιn-3-ylamιno)-methyl]-3,4-dιhydro-1 H- quιnolιn-2-one, [2-Methoxy-5-(2,2,2-tπfluoro-1 -tπfluoromethyl-ethyl)-benzy!]-(2-phenyl-pιperιdιn-3-yl)- amine, [5-(1 , 1 -Dιmethyl-prop-2-ynyl)-2-methoxy-benzyl]-(2-phenyl-pιperιdιn-3-yl)-amιne, 7-Methoxy-1 -methyl-6-[(2-phenyl-pιperιdιn-3-ylamιno)-methyl]-3,4-dιhydro-1 H- quιnolιn-2-one, [2-Methoxy-5-(2,2,2-tπfluoro-1 ,1 -dιmethyl-ethyl)-benzyl]-(2-phenyi-pιpeπdιn-3-yl)- amine, (7-Methoxy-4-methyl-3 4-dιhydro-2H-benzo[1 ,4]oxazιn-6-ylmethyl)-(2-phenyl- pιpeπdιn-3-yl)-amιne, [2-Methoxy-5-(1 -methyl-1 -trιfluoromethyl-prop-2-ynyl)-benzyl]-(2-phenyl-pιperιdιn-3- yl)-amιne, (6-Methoxy-1 -methyl-1 -tπfluoromethyl-ιsochroman-7-ylmethyl)-(2-phenyl-pιpeπdιn-3- yl)-amιne, 2-{3-[(2-Benzhydryl-1 -aza-bιcyclo[2 2 2]oct-3-ylamιno)-methyl]-4- methoxy-phenyl}-2- methyl-propan-1 -ol, (2S,3S)-N-[(5-oxo-1 H,4H-1 ,2,4-trιazolo)methyl]-2-(4-fluoropheπyl)-3-(3,5- dιtrιfluoromethyl)benzyloxymorpholιne, 3-(3 , 5-Bιs-tπfluoromethyl-benzyioxy)-2-phenyl-pιpeπdιne, 5-[2-(3,5-Bιs-trιfluoromethyl-beπzyloxy)-3-phenyl-morpholιn-4-ylmethyl]-2 4-dιhydro- [1 ,2,4]trιazol-3-one, (2S 3S)-3-(2-Methoxy-5-(trιfluoromethoxy)benzyl)amιno-2-phenylpιperιdιne, (2S, 3S)-N-(5-ιsopropyl-2-methoxyphenyl)methyl-2-dιphenylmethyl-1 - azabιcyclo[2 2 2]-octan-3-amιne, (2S, 3S)-N-(5-tert-butyl-2-methoxyphenyl)methyl-2-dιphenylmethyl-1 - azabιcyclo[2 2 2]-octane-3-amιne, (2S 3S)-N-(5-ethyl-2-methoxyphenyl)methyl-2-dιphenylmethyl-1 -azabιcyclo[2 2 2]- octan-3-amιne, and (2S,3S)-N-(5-n-propyl-2-methoxyphenyl)methyl-2-dιpheπylmethyl-1 -azabιcyclo[2 2 2]- octane-3-amιne or a pharmaceutically acceptable salt or an optical isomer thereof 21 The method according to claim 18 wherein the COX 2 inhibitor analgesic agent is selected from rofecoxib and celecoxib their pharmaceutically active salts and their optical isomers 22 The method according to Claim 18 wherein the anesthetic analgesic agent agent is selected from nitrous oxide halothane, lidocaine etidocaine, ropivacaine, chloroprocaine, sarapin and buDivacaine their pharmaceutically active salts and their optical isomers 23 The method according to Claim 18 wherein the benzodiazepine analgesic agent is selected from diazepam chlordiazepoxide, alprazolam, and lorazepam their pharmaceutically active salts and their optical isomers 24 The method according to Claim 18 wherein the skeletal muscle relaxant analgesic agent is selected from flexeπl, caπsoprodol, robaxisal, norgesic and dantπum their pharmaceutically active salts and their optical isomers 25 The method according to Claim 18 wherein the migraine therapeutic agent is selected from elitriptan sumatriptan rizatriptan, zolmitnptan, and naratnptan their pharmaceutically active salts and their optical isomers 26 The method according to Claim 18 wherein the anticonvulsant analgesic agent is selected from gabapentin pregabalin carbamazepine, and topiramate and valproic acid their pharmaceutically active salts and their optical isomers 27 The method according to Claim 18 wherein the COX 1 inhibitor analgesic agent is selected from salycy c acid, acetominophen, diclofenac, piroxican indomethacin, ibuprofen, and naproxen their pharmaceutically active salts and their optical isomers 28 The method according to Claim 18 wherein the tricyclic antidepressant analgesic agent is selected from amitnptyline, desipramine, perphenazine, protnptyline, and tranyicypromine their pharmaceutically active salts and their optical isomers 29 The method according to Claim 18 wherein the analgesic agent is chosen from baclofen, clonidine, mexilitene, diphenyl-hydramine, hydroxysine, caffeine, prednisone, methylprednisone, decadron, paroxetine, sertraline, fluoxetine, tramodol, Ziconotide® and levodopa their pharmaceutically active salts and their optical isomers 30 The method according to claim 17, wherein the nicotine partial agonist is selected from 9-bromo-1 ,2,3 4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-chloro-1 ,2,3,4,5,6-hexahydro-1 5-methano-pyrιdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-fluoro-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-ethyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-methyl-1 ,2,3 4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-phenyl-1 ,2,3,4,5,6-hexahydro-1 5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-vιnyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyr ιdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-bromo-3-methyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2-a][1 ,5]dιazocιn-8- one, 3-benzyl-9-bromo-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8- one, 3-benzyl-9-chloro-1 ,2,3 4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2-a][1 ,5]dιazocιn-8- one, 9-acetyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-ιodo-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-cyano-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-ethynyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-(2-propenyl)-1 ,2,3,4,5,6-hexahydro-1 ,5-methaπo-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-(2-propyl)- 1 ,2,3,4,5 6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-carbomethoxy-1 ,2,3,4 5 6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-carboxyaldehyde-1 ,2 3 4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-(2 6-dιfluorophenyl)-1 2,3,4 5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-phenyl-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-(2-fluorophenyl)-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8- oπe 9-(4-fluorophenyl)-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyndo[1 ,2a][1 ,5]dιazocιn-8- one 9-(3-fluorophenyl)-1 ,2,3,4,5 6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8- one 9-(3 5-dιfluorophenyl)-1 ,2,3 4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8- one 9-(2 4-dιfluorophenyl)-1 ,2,3 4 5 6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-(2 5-dιfluorophenyl)-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8- one 6-methyl-5-oxo-6, 13-dιazatetracyclo[9 3 1 0 2 10 0 4 8 ]pentadeca-2(10),3,8-tπene, 5-0X0-6, 13-dιazatetracyclo[9 3 1 0 2 10 0 4 8 ]pentadeca-2(10),3,8-tπene, 6-0X0-5,7, 13-tπazatetracyclo[9 3 1 0 2 10 0 4 8 ]pentadeca-2(10),3,8-tπene, 4 5-dιfluoro-10-aza-trιcyclo[6 3 1 0 2 " ]dodeca-2(7),3,5-tπene, 5-fluoro-10-aza-trιcyclo[6 3 1 0 2 7 ]dodeca-2(7),3,5-trιene-4-carbonιtrιle, 4-ethynyl-5-fluoro-10-aza-trιcyclo[6 3 1 0 2 7 ]dodeca-2(7),3,5-tπene, 5-ethynyl-10-aza-trιcyclo[6 3 1 0 2 7 ]dodeca-2(7),3,5-tπene-4-carbonιtπle, 6-methyl-5-thιa-5-dιoxa-6, 13-dιazatetracyclo[9 3 1 0 2 10 0 4 8 ]pentadeca-2(10),3,8- tπene, 10-aza-trιcyclo[6 3 1 0 2 7 ]dodeca-2(7),3,5-trιene, 4-fluoro-10-aza-trιcyclo[6 3 1 0 2 7 ]dodeca-2(7),3,5-tπene, 4-methyl-10-aza-trιcyclo[6 3 1 0 2 7 ]dodeca-2(7),3,5-trιene 4-tπfluoromethyl-10-aza-tπcyclo[6 3 1 0 2 ']dodeca-2(7),3,5-trιene, 4-nιtro-10-azatπcyclo[6 3 1 0 2 7 ]dodeca-2(7),3,5-trιene, 7-methyl-5,7, 13-tπazatetracyclo[9 3 1 0 2 10 0 8 ]pentadeca-2(10), 3, 5, 8-tetraene, 6-methyl-5,7, 13-tπazatetracyclo[9 3 1 0 2 10 0 4 8 ]pentadeca-2(10), 3,5, 8-tetraene, 6,7-dιmethyl-5,7, 13-tπazatetracycio[9 3 1 0 2 10 0 4 8 ]pentadeca-2(10), 3, 5,8-tetraene, 6-methyl-7-phenyl-5,7 13-tπazatetracyclo[9 3 1 0 2 10 0 4 8 ]pentadeca-2(10),3, 5,8- tetraene 6 7-dιmethyl-5 8 14-tπazatetracyclo[10 3 1 0 2 1 1 0 4 ]hexadeca-2(1 1 ),3,5,7,9-pentaene, 5,8 14-trιazatetracyclo[10 3 1 0 2 0 4 9 ]hexadeca-2(1 1 ),3, 5,7, 9-pentaene, 14-methyl-5,8 14-tπazatetracyclo[10 3 1 0 2 1 1 0 4 9 ]hexadeca-2(1 1 ),3,5,7,9-pentaene, 5-oxa-7 13-dιazatetracyclo[9 3 1 0 2 10 0 4 8 ]pentadeca-2(10), 3, 6, 8-tetraene, 6-methyl-5-oxa-7,13-dιazatetracyclo[9310 210 0 48 ]pentadeca-2(10),3, 6, 8-tetraene, 4-chloro-10-azatrιcyclo[6310 27 ]dodeca-2(7),3,5-trιene, 10-azatπcyclo[6310 27 ]dodeca-2(7),3,5-tπen-4-yl cyanide, 1-(10-azatrιcyclo[6310 27 ]dodeca-2(7),3,5-tπen-4-yl)-1-ethanone, 10-azatπcyclo[6310 2" ]dodeca-2(7),3,5-tπen-4-ol, 7-methyl-5-oxa-6,13-dιazatetracyclo[9310 210 0 48 ]pentadeca-24(8),6,9-tetraene, 4,5-dιchloro-10-azatπcyclo[6310 27 ]dodeca-2(7),3,5-tπene, 11-azatrιcyclo[7310 2" ]trιdeca-2(7),3,5-trιene-5-carbonιtrιle, 1-[11-azatrιcyclo[7310 27 ]trιdeca-2(7),3,5-trιen-5-yl]-1-ethanone, 1-[11-azatrιcyclo[7310 27 ]tπdeca-2(7),3,5-trιen-5-yl]-1-propanone, 4-fluoro-11-azatrιcyclo[7310 27 ]tπdeca-2(7),3,5-trιene-5-carbonιtrιle, 5-fluoro-11-azatπcyclo[7310 27 ]tπdeca-2(7),3,5-trιene-4-carbonιtrιle, 6-methyl-7-thιa-5,14-dιazatetracyclo[10310 210 0 48 ]hexadeca-2(10), 3, 5,8-tetraene, 6-methyl-5,714-tπazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3, 5,8-tetraene, 67-dιmethyl-5,714-tπazatetracyclo[10310 210 0 48 ]hexadeca-2(10), 3, 5,8-tetraene, 57,14-tπazatetracyclo[10310 2 0 0 48 ]hexadeca-2(10),3, 5, 8-tetraene, 5,6-dιmethyl-5,7,14-tπazatetracyclo[10310 210 0 48 ]hexadeca-2(10), 3,6, 8-tetraene, 5-methyl-5,7,14-tπazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3, 6,8-tetraene, 6-(tπfluoromethyl)-7-thιa-514-dιazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3,5,8- tetraene, 5,8,15-trιazatetracyclo[11310 211 0 49 ]heptadeca-2(11), 3, 5, 7, 9-pentaene, 7-methyl-5,815-tπazatetracyclo[1131 O 211 0 49 ]heptadeca-2(11),3, 5, 7, 9-pentaene, 6-methyl-58,15-tπazatetracyclo[1131 O 211 0 49 ]heptadeca-2(11 ), 3, 5, 7, 9-pentaene, 6,7-dιmethyl-5,8,15-tπazatetracyclo[11310 211 0 49 ]heptadeca-2(11 ), 3, 5,7,9- pentaene, 7-oxa-5, 14-dιazatetracyclo[10310 210 0 8 ]hexadeca-2(10),3, 5, 8-tetraene, 6-methyl-7-oxa-5,14-dιazatetracyclo[1031 O 210 0 48 ]hexadeca-2(10),3,5,8-tetraene, 5-methyl-7-oxa-6,14-dιazatetracyclo[10310 210 0 48 ]hexadeca-2(10),3, 5,8-tetraene, 6-methyl-5-oxa-714-dιazatetracyclo[10310 210 0 8 ]hexadeca-2(10),3,6, 8-tetraene, 7-methyl-5-oxa-614-dιazatetracyclo[10310 210 0 8 ]hexadeca-2(10), 3, 6,8-tetraene, 4,5-dιfluoro-11-azatπcyclo[7310 27 ]tπdeca-2(7),3,5-tπene, 4-chloro-5-fluoro-11-azatπcyclo[7310 27 ]trιdeca-2(7),3,5-trιene, 5-chloro-4-fluoro-11-azatπcyclo[7310 2 ']trιdeca-2(7),3,5-trιene, 4-(1-ethynyl)-5-fluoro-11-azatrιcyclo[7310 27 ]trιdeca-2(7),35-trιene, 5-(1-ethynyl)-4-fluoro-11-azatrιcyclot7310 27 ]trιdeca-2(7),3,5-trιene, 5,6-dιfluoro-11-aza-tπcyclo[731 O 27 ]trιdeca-24,6-tπene, 6-tπfluoromethyl-1 1 -aza-trιcyclo[7 3 1 0 2 7 ]trιdeca-2,4,6-trιeπe, 6-methoxy-1 1 -aza-tπcyclo[7 3 1 0 2 7 ]tπdeca-2(7),3,5-tπene, 1 1 -aza-trιcyclo[7 3 1 0 2 _ ]trιdeca-2(7),3,5-trιen-6-ol, 6-fluoro-1 1 -aza-trιcyclo[7 3 1 0 2 7 ]tπdeca-2(7),3,5-trιene, 1 1 -aza-trιcyclo[7 3 1 0 2 " ]tπdeca-2(7),3,5-tπen-5-ol, 4-nιtro-1 1 -aza-trιcyclo[7 3 1 0 2 " ]tπdeca-2(7),3,5-tπene, 5-nιtro-1 1 -aza-tπcyclo[7 3 1 0 2 7 ]trιdeca-2(7),3,5-tπene, 5-fluoro-1 1 -aza-tπcyclo[7 3 1 0 2 7 ]trιdeca-2(7),3,5-tπene, 6-hydroxy-5-methoxy-1 1 -aza-trιcyclo[7 3 1 0 2 7 ]trιdeca-2(7),3,5-trιene and a pharmaceutically acceptable salt and an optical isomer thereof 31 The method according to claim 30 wherein the nicotine partial agonist is selected from 9-bromo-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8-oπe, 9-chioro-1 ,2 3,4,5 6-hexahydro-1 ,5-methano-pyπdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-fluoro-1 ,2,3,4,5 6-hexahydro-1 ,5-methano-pyrιdo[1 ,2-a][1 ,5]dιazocιn-8-one, 9-acetyl-1 ,2,3,4,5 6-hexahydro-1 5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-ιodo-1 ,2 3 4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-cyano-1 ,2,3 4,5 6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-carbomethoxy-1 ,2,3,4,5,6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8-one, 9-carboxyaldehyde-1 2 3,4,5,6-hexahydro-1 ,5-methano-pyrιdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-(2 6-dιfluorophenyl)-1 ,2 3,4,5 6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8- one, 9-phenyl-1 ,2 3,4 5 6-hexahydro-1 ,5-methano-pyrιdo[1 2a][1 5]dιazocιn-8-one, 9-(2-fluorophenyl)-1 ,2 3 4,5 6-hexahydro-1 ,5-methano-pyπdo[1 ,2a][1 ,5]dιazocιn-8- one, 6-methyl-5-thιa-5-dιoxa-6 13-dιazatetracyclo[9 3 1 0 2 10 0 4 8 ]pentadeca-2(10),3,8- tπene, 4-fluoro-10-aza-tπcyclo[6 3 1 0 ' ]dodeca-2(7),3.5-tπene, 4-trιfluoromethyl-10-aza-tπcycio[6 3 1 0 2 ' ]dodeca-2(7),3,5-trιene, 4-nιtro-10-azatπcyclo[6 3 1 0 " ]dodeca-2(7) 3,5-tπene, 6-methyl-5,7, 13-tπazatetracyclo[9 3 1 0 2 10 0 4 8 ]pentadeca-2(10), 3, 5, 8-tetraene, 6,7-dιmethyl-5,8 14-tπazatetracyclo[10 3 1 0 2 1 0 4 9 ]hexadeca-2(1 1 ),3,5,7,9-pentaene, 5,8 14-tπazatetracyclo[10 3 1 0 2 1 1 0 4 9 ]hexadeca-2(1 1 ),3,5,7,9-pentaene, 5-oxa-7, 13-dιazatetracyclo[9 3 1 0 2 10 0 8 ]pentadeca-2(10), 3, 6, 8-tetraene, 6-methyl-5-oxa-7 13-dιazatetracyclo[9 3 1 0 2 10 0 4 δ ]pentadeca-2(10), 3, 6, 8-tetraene, 10-azatrιcyclo[6 3 1 0 ' ]dodeca-2(7), 3, 5-trιen-4-yl cyanide, 1 -( 10-azatπcyclo[6 3 1 0 2 " ]dodeca-2(7),3,5-tπen-4-yl)-1 -ethanone, 1 1 -azatrιcyclo[7 3 1 0 2 " ]trιdeca-2(7),3,5-trιene-5-carbonιtπle, 1 -[1 1 -azatrιcyclo[7 3 1 0 2 7 ]trιdeca-2(7),3,5-tπen-5-yl]-1 -ethanone, 1 -[1 1 -azatπcyclo[7 3 1 0 2 7 ]trιdeca-2(7),3,5-trιen-5-yl]-1 -propanone, 4-fluoro-1 1 -azatπcyclo[7 3 1 0 2 ']tπdeca-2(7),3,5-tπene-5-carbonιtπle, 5-fluoro-1 1 -azatπcyclo[7 3 1 0 2 7 ]tπdeca-2(7),3,5-tπene-4-carbonιtπle, 6-methyl-7-thιa-5, 14-dιazatetracyclo[10 3 1 0 2 10 0 4 8 ]hexadeca-2(10),3, 5,8-tetraene, 6-methyl-5,7 14-trιazatetracyclo[10 3 1 0 2 10 0 4 8 ]hexadeca-2(10),3, 5,8-tetraene, 6.7-dιmethyl-5 7, 14-trιazatetracyclo[10 3 1 0 2 10 0 4 8 ]hexadeca-2(10),3, 5, 8-tetraene, 6-methyl-7-oxa-5, 14-dιazatetracyclo[10 3 1 0 2 10 0 8 ]hexadeca-2(10),3, 5,8-tetraene, 6-methyl-5-oxa-7, 14-dιazatetracyclo[10 3 1 0 2 10 0 4 8 ]hexadeca-2(10),3,6,8-tetraene, 5,6-dιfluoro-1 1 -aza-tπcyclo[7 3 1 0 2 7 ]tπdeca-2,4,6-tπene, 6-trιfluoromethyl-1 1 -aza-trιcyclo[7 3 1 0 2 ']trιdeca-2,4,6-trιene, 6-methoxy-1 1 -aza-tπcyclo[7 3 1 0 2 7 ]tπdeca-2(7),3,5-tπene, 6-fluoro-1 1 -aza-tπcyclo[7 3 1 0 2 7 ]tπdeca-2(7),3,5-trιene, 1 1 -aza-tπcyclo[7 3 1 0 2 ]tπdeca-2(7),3,5-trιen-5-ol, and the pharmaceutically acceptable salts and optical isomers thereof 32 The method according to claim 17, wherein the nicotine receptor partial agonist and the analgesic agent are administered substantially simultaneously 33 A pharmaceutical composition for treating a disorder or condition selected from the group consisting of diseases and conditions in which pain predominates, including acute pain, chronic pain, neuropathic pain and migraine, and including soft tissue and peripheral damage such as acute trauma, osteoarthπtis, rheumatoid arthritis, musculo- skeletal pain, particularly after trauma spinal pain, dental pain myofascial pain syndromes, headache, episiotomy pain and burns, deep and visceral pain, such as heart pain, muscle pain, eye pain orofacial pain for example, odontalgia, abdominal pain, gynaecological pain, for example, dysmenorrhea, and labor pain, pain associated with nerve and root damage, such as pain associated with peripheral nerve disorders, for example, nerve entrapment and brachial plexus avulsions, amputation, peripheral neuropathies, tic douloureux, atypical facial pain, nerve root damage, and arachnoiditis, pain associated with carcinoma, often referred to as cancer pain, central nervous system pain, such as pain due to spinal cord or brain stem damage, low back pain, sciatica headache, including migraine, acute or chronic tension headache cluster headache, temporomandibular pain and maxillary sinus pain, ankylosmg spondy tis, gout, post operative pain, and scar pain, in a mammal including a human, the method comprising administering to said mammal respectively a pain attenuating effective amount of a pharmaceutical composition comprising (a) a nicotine receptor partial agonist or a pharmaceutically acceptable salt thereof, (b) an analgesic agent or a pharmaceutically acceptable salt thereof and (c) a pharmaceutically acceptable carrier, wherein the active agents "a" and "b" above are present in amounts that render the composition effective in treating acute, chronic and/or neuropathic pain and migraine 34 A method of treating a disorder or condition selected from the group consisting of diseases and conditions in which pain predominates, including acute pain, chronic pain neuropathic pain and migraine, and including soft tissue and peripheral damage, such as acute trauma, osteoarthπtis, rheumatoid arthritis, musculo- skeletal pain, particularly after trauma, spinal pain, dental pain, myofascial pain syndromes, headache, episiotomy pain, and burns, deep and visceral pain, such as heart pain, muscle pain, eye pain, orofacial pain, for example, odontalgia, abdominal pain, gynaecological pain, for example, dysmenorrhea, and labor pain, pain associated with nerve and root damage, such as pain associated with peripheral nerve disorders for example, nerve entrapment and brachial plexus avulsions, amputation, peripheral neuropathies, tic douloureux, atypical facial pain, nerve root damage, and arachnoiditis, pain associated with carcinoma, often referred to as cancer pain, central nervous system pain such as pain due to spinal cord or brain stem damage, low back pain, sciatica, headache, including migraine, acute or chronic tension headache, cluster headache, temporomandibular pain and maxillary sinus pain, ankylosing spondylitis, gout, post operative pain, and scar pain, in a mammal, including a human, the method comprising administering to said mammal respectively a pain attenuating effective amount of a pharmaceutical composition comprising (a) a nicotine receptor partial agonist or a pharmaceutically acceptable salt thereof, (b) an analgesic agent or a pharmaceutically acceptable salt thereof and (c) a pharmaceutically acceptable carrier, wherein the active agents "a" and "b" above are present in amounts that render the composition effective in treating acute, chronic and/or neuropathic pain and migraine

Inventors: COE JOTHAM WADSWORTH, HARRIGAN EDMUND PATRICK, O'NEILL BRIAN THOMAS, SANDS STEVEN BRADLEY, WATSKY ERIC JACOB, COE, JOTHAM, WADSWORTH, HARRIGAN, EDMUND, PATRICK, O'NEILL, BRIAN, THOMAS, SANDS, STEVEN, BRADLEY, WATSKY, ERIC, JACOB
Applicants: COE JOTHAM WADSWORTH, HARRIGAN EDMUND PATRICK, NEILL BRIAN THOMAS O, PFIZER PROD INC, SANDS STEVEN BRADLEY, WATSKY ERIC JACOB, COE, JOTHAM, WADSWORTH, HARRIGAN, EDMUND, PATRICK, O'NEILL, BRIAN, THOMAS, PFIZER PRODUCTS INC., SANDS, STEVEN, BRADLEY, WATSKY, ERIC, JACOB
Application year: 2001
Main classification: A61K31
IPC codes: A61K31, A61K45, A61P25, A61P29, A61P43